US20090124996A1 - Apparatus and methods for injecting high viscosity dermal fillers - Google Patents
Apparatus and methods for injecting high viscosity dermal fillers Download PDFInfo
- Publication number
- US20090124996A1 US20090124996A1 US12/114,194 US11419408A US2009124996A1 US 20090124996 A1 US20090124996 A1 US 20090124996A1 US 11419408 A US11419408 A US 11419408A US 2009124996 A1 US2009124996 A1 US 2009124996A1
- Authority
- US
- United States
- Prior art keywords
- needle
- pressurized fluid
- distal end
- end portion
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000002500 effect on skin Effects 0.000 title claims abstract description 185
- 239000000945 filler Substances 0.000 title claims abstract description 185
- 238000000034 method Methods 0.000 title claims abstract description 45
- 239000003814 drug Substances 0.000 claims description 278
- 239000012530 fluid Substances 0.000 claims description 141
- 230000001105 regulatory effect Effects 0.000 claims description 38
- 230000008878 coupling Effects 0.000 claims description 33
- 238000010168 coupling process Methods 0.000 claims description 33
- 238000005859 coupling reaction Methods 0.000 claims description 33
- 238000002347 injection Methods 0.000 claims description 26
- 239000007924 injection Substances 0.000 claims description 26
- 238000004891 communication Methods 0.000 claims description 9
- 230000001815 facial effect Effects 0.000 claims description 5
- 206010033675 panniculitis Diseases 0.000 claims description 3
- 210000004304 subcutaneous tissue Anatomy 0.000 claims description 3
- 238000004146 energy storage Methods 0.000 claims 4
- 210000003491 skin Anatomy 0.000 description 45
- 239000011324 bead Substances 0.000 description 19
- 230000007246 mechanism Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 210000004872 soft tissue Anatomy 0.000 description 6
- 230000003321 amplification Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000000881 depressing effect Effects 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920001432 poly(L-lactide) Polymers 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000005070 sphincter Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- RWIUTHWKQHRQNP-ZDVGBALWSA-N (9e,12e)-n-(1-phenylethyl)octadeca-9,12-dienamide Chemical compound CCCCC\C=C\C\C=C\CCCCCCCC(=O)NC(C)C1=CC=CC=C1 RWIUTHWKQHRQNP-ZDVGBALWSA-N 0.000 description 1
- 229920001823 Aquamid® Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229920001954 Restylane Polymers 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000501 collagen implant Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 108010089886 dermicol-P35 27G Proteins 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0059—Cosmetic or alloplastic implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
- A61M5/1452—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M5/2053—Media being expelled from injector by pressurised fluid or vacuum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/3129—Syringe barrels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31511—Piston or piston-rod constructions, e.g. connection of piston with piston-rod
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3128—Incorporating one-way valves, e.g. pressure-relief or non-return valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/002—Packages specially adapted therefor, e.g. for syringes or needles, kits for diabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31511—Piston or piston-rod constructions, e.g. connection of piston with piston-rod
- A61M5/31513—Piston constructions to improve sealing or sliding
Definitions
- the invention relates generally to medical devices and methods, and more particularly to medical devices and methods for injecting high viscosity dermal fillers into a body.
- High viscosity medicaments such as dermal fillers, can be injected into the body to augment soft tissue portions within the body.
- high viscosity compositions can be injected adjacent the urinary sphincter muscle to increase the volume of the tissue within the urinary tract to treat urinary incontinence.
- High viscosity compositions can also be injected into the skin to change the contour of and/or increase the volume of the skin.
- known high viscosity compositions can be injected within facial skin to remove wrinkles, treat scars or the like.
- Some known procedures for injecting high viscosity dermal fillers include injecting the dermal filler using a standard syringe.
- the force and/or pressure required to convey the dermal filler from the syringe body through the needle can be generated manually by having the user manually depress a plunger into the syringe body.
- the force generated by manually depressing a plunger can be sporadic, thus resulting in undesirable fluctuations in the flow of the dermal filler through the needle, which can result in the user injecting more or less dermal filler at a particular location within the body than is desired. Generating the injection force and/or pressure manually can also result in inconsistent results between different users.
- the force generated by manually depressing a plunger can be insufficient to provide the desired flow rate of dermal filler.
- the total volume of dermal filler injected is a function of the length of travel of the plunger, it can be difficult to deliver a sufficient volume of dermal filler when injecting the dermal filler manually using a standard syringe.
- generating the injection force and/or pressure manually can result in user fatigue and/or chronic health problems for the user, such as, for example arthritis.
- a method includes inserting a distal end portion of a needle of a medical injector into a skin of a body.
- An energy source operatively coupled to the medical injector is actuated such that a dermal filler is conveyed from the medical injector into the skin through the distal end portion of the needle.
- the distal end portion of the needle is moved within the skin during the actuating.
- FIG. 1 is a flow chart illustrating a method of assembling a medical injector according to an embodiment.
- FIGS. 2-4 are schematic illustration showing a portion of a body B containing a dermal filler in a first configuration, a second configuration and a third configuration, respectively, according to the method illustrated in FIG. 1 .
- FIG. 5 is schematic illustration showing a portion of a body B containing a dermal filler injected therein by a method according to an embodiment.
- FIGS. 6 and 7 are schematic illustrations of a medical device according to an embodiment, in a first configuration and a second configuration, respectively.
- FIG. 8 is a side view of a portion of a system for injecting dermal fillers according to an embodiment.
- FIGS. 9 and 10 are perspective views of a portion of the system for injecting dermal fillers shown in FIG. 8 .
- FIG. 11 is a side view of a portion of a system for injecting dermal fillers according to an embodiment.
- FIG. 12 is a side view of a portion of a system for injecting dermal fillers including a pressure amplifier according to an embodiment.
- FIG. 13 is a perspective view of a portion of a system for injecting dermal fillers according to an embodiment.
- FIG. 14 is a perspective view of a system for injecting dermal fillers including a self-contained source of pressurized fluid according to an embodiment.
- FIG. 15 is a perspective view of a portion of the system for injecting dermal fillers shown in FIG. 14 .
- FIG. 16 is an exploded view of the portion of the system for injecting dermal fillers shown in FIG. 15 .
- FIG. 17 is a cross-sectional view of the portion of the system for injecting dermal fillers shown in FIG. 15 .
- a method includes inserting a distal end portion of a needle of a medical injector into a skin of a body.
- the skin can include, for example, facial skin.
- An energy source operatively coupled to the medical injector is actuated such that a dermal filler is conveyed from the medical injector into the skin through the distal end portion of the needle.
- the energy source can include, for example, a pressurized fluid configured to move a piston within the medical injector. The distal end portion of the needle is moved within the skin during the actuating.
- a non-manually-powered machine operatively coupled to the medical injector is actuated such that a dermal filler is conveyed from the medical injector into the skin through the distal end portion of the needle.
- the method can include regulating a flow rate of the dermal filler through the distal end portion of the needle during the actuating.
- proximal and distal refer to direction closer to and away from, respectively, an operator (e.g., surgeon, physician, nurse, technician, etc.) of the medical device.
- an operator e.g., surgeon, physician, nurse, technician, etc.
- the end of the medicament delivery device contacting the patient's body would be the distal end of the medicament delivery device, while the end opposite the distal end would be the proximal end of the medicament delivery device.
- an apparatus for non-manually injecting a dermal filler can include any apparatus in which the force to inject the dermal filler is not directly produced by a human.
- a non-manual injection apparatus include an apparatus having a compressed gas source to provide the injection force, an apparatus having a spring to provide the injection force, and an apparatus having an electric motor to provide the injection force.
- An apparatus for non-manually injecting a dermal filler can include a manual actuator (e.g., an on/off switch, a push button, a foot pedal or the like) to initiate the non-manual injection.
- FIG. 1 is a flow chart illustrating a method 10 of injecting a dermal filler according to an embodiment.
- FIGS. 2-4 are schematic illustrations showing a portion of a body B containing a dermal filler 118 injected therein according to the method 10 , in a first configuration, a second configuration and a third configuration, respectively.
- the illustrated method includes inserting a distal end portion of a needle of a medical injector into a skin of a body, at 12 .
- the skin can be disposed at any location of the body, such as for example, facial skin.
- the distal end portion 122 of the needle 120 is inserted into the skin SK in a distal direction as shown by the arrow AA.
- the needle 120 is inserted into the skin SK at an angle ⁇ relative to the surface of the skin SK and at depth d within the body B.
- the needle 120 can be inserted into the skin SK at any suitable angle ⁇ and at any suitable depth d for achieving the desired result.
- the needle 120 is inserted into the skin SK at an angle ⁇ of between 5 and 35 degrees.
- the needle 120 is inserted into the skin SK at an angle ⁇ of approximately 20 degrees.
- the needle 120 is inserted into the skin SK at a depth d of between 1.5 and 6 millimeters.
- the needle 120 is inserted into the skin SK at a depth d of between approximately 1.5 and 2 millimeters.
- the distal end portion 122 of the needle 120 is shown as being inserted into the subcutaneous tissue S of the skin SK, in some embodiments, the distal end portion 122 of the needle 120 can be inserted into the epidermis E and/or the dermis D of the skin SK. In other embodiments, the distal end portion 122 of the needle 120 can be inserted below the subcutaneous tissue S. In yet other embodiments, the distal end portion 122 of the needle 120 can be inserted through the skin SK into another portion of the body B, such as for example a urinary sphincter (not shown in FIGS. 2-5 ).
- an energy source operatively coupled to the medical injector is actuated such that a dermal filler is conveyed from the medical injector into the skin through the distal end portion of the needle, at 14 .
- the energy source 150 is actuated via an actuator 153 .
- the energy source 150 can include any suitable form of energy that can act upon the medical injector 100 to convey the dermal filler 118 from the medical injector 100 through the distal end portion 122 of the needle 120 .
- the energy source 150 can include a pressurized gas that exerts a force on a portion of the medical injector 100 .
- the dermal filler 118 When the energy source 150 is actuated by the actuator 153 , the dermal filler 118 is conveyed from the medical injector 100 through the distal end portion 122 of the needle 120 . In this manner, the dermal filler 118 can be injected into the body B non-manually. Said another way, the dermal filler 118 can be injected into the body B without the user producing the energy necessary for the injection.
- the distal end portion of the needle is moved within the skin when the energy source is being actuated, at 16 .
- the user can vary the location of the distal end portion of the needle within the skin when the dermal filler is being injected into the body B.
- the distal end portion 122 of the needle 120 is moved in a proximal direction, as shown by the arrow BB, when the energy source 150 is being actuated.
- the user can inject a substantially continuous bead of dermal filler 118 along a desired passageway (e.g., a wrinkle) within the skin SK.
- the distal end portion 122 of the needle 120 is moved in a direction substantially opposite the direction of flow of the dermal filler 118 from the distal end portion 122 of the needle 120 (shown by the arrow CC in FIG. 4 ).
- the dermal filler 118 is conveyed from the distal end portion 122 of the needle 120 non-manually, the user is not burdened with producing a force in the distal direction (to inject the dermal filler 118 ) while simultaneously moving the distal end portion 122 of the needle 120 in the proximal direction.
- the operation of producing a force to inject the dermal filler 118 is independent from the operation of moving the distal end portion 122 of the needle 120 .
- the operation of producing a force to inject the dermal filler 118 is decoupled from (i.e., is separate and distinct from) the operation of moving the distal end portion 122 of the needle 120 .
- This arrangement can result in a repeatable, continuous and/or controlled movement of the distal end portion 122 of the needle 120 and/or injection of the dermal filler 118 .
- some known medical injectors require the user to use the same hand to produce a force in a distal direction along a longitudinal axis of the medical injector to inject a dermal filler and move the needle along the longitudinal axis, for example, in an opposite (i.e., proximal) direction.
- the injection of the dermal filler can be irregular, uncontrolled and/or discontinuous.
- the disadvantage of such manual injection procedures can be exacerbated when injecting high viscosity dermal fillers, because, as described herein, the force to inject such dermal fillers can be in excess of approximately 4.5 N (10 lbf).
- the force to inject such dermal fillers can be in excess of approximately 4.5 N (10 lbf).
- the resulting bead of dermal filler can have undesirable spatial variability in its size and/or volume.
- the distal end portion 122 of the needle 120 is shown and described above as being moved in the proximal direction when the energy source 150 is being actuated, in other embodiments, the distal end portion 122 can be moved in any manner.
- the distal end portion 122 of the needle 120 can be moved in a distal direction (i.e., in substantially the same direction as the flow of the dermal filler 118 from the distal end portion 122 of the needle 120 ).
- the distal end portion 122 of the needle 120 can be moved in a direction not parallel to a longitudinal axis of the needle 120 .
- the distal end portion 122 of the needle 120 can be rotated when the energy source 150 is being actuated.
- the user can “fan” the distal end portion 122 of the needle 120 (i.e., move the distal end portion 122 in a direction not parallel to a longitudinal axis of the needle 120 ) within the skin SK when the energy source is being actuated.
- the distal end portion 122 of the needle 120 can be moved any suitable distance when the energy source 150 is being actuated. In some embodiments, for example, the distal end portion 122 of the needle 120 can be moved a distance of at least 4 millimeters during actuation of the energy source 150 .
- the method can optionally include regulating a flow rate of the dermal filler through the distal end portion of the needle when the energy source is being actuated, at 18 .
- the user can adjust the amount the dermal filler being injected within and/or beneath the skin to provide the desired cosmetic and/or therapeutic results.
- the flow rate of the dermal filler can be regulated to maintain a substantially constant flow rate of the dermal filler through the distal end portion of the needle when the distal end portion of the needle is moved within and/or beneath the skin.
- the flow rate of the dermal filler can be regulated to produce a substantially uniform bead of dermal filler within the skin.
- the flow rate of the dermal filler can be regulated when the needle is moved within the skin to produce a substantially uniform bead of dermal filler having a volume of approximately 1 to 2 cubic centimeters and a length of between approximately 4 millimeters and 13 millimeters.
- the flow rate of the dermal filler can be regulated when the needle is moved within the skin to produce a substantially uniform bead of dermal filler having a volume of less than 1 cubic centimeter and a length of between approximately 4 millimeters and 13 millimeters.
- the flow rate of the dermal filler can be regulated when the needle is moved within the skin to produce a substantially uniform bead of dermal filler having a volume of approximately 0.1 to 0.2 cubic centimeter and a length of between approximately 4 millimeters and 13 millimeters.
- the flow rate of the dermal filler can be regulated when the needle is moved within the skin to produce a substantially uniform bead of dermal filler having a volume of greater than 2 cubic centimeter (e.g., a volume of 3, 4, 5, or 10 cubic centimeters) and a length of up to 150 millimeters.
- Such a bead can be used, for example, to increase the skin volume in the areas of the nasal labial fold, the jowls and/or the neck region, and can smooth the appearance of wrinkles in those areas.
- the flow rate of the dermal filler can be regulated to produce any suitable flow rate.
- the flow rate of the dermal filler can be regulated to a substantially constant flow rate of at least approximately 0.02 cubic centimeters per minute.
- the flow rate of the dermal filler can be regulated to a substantially constant flow rate of between approximately 0.02 cubic centimeters per minute and 0.5 cubic centimeters per minute.
- the flow rate of the dermal filler can be regulated to a substantially constant flow rate of as much as 3 cubic centimeters per minute.
- the flow rate of the dermal filler can be regulated to a substantially constant flow rate greater than 3 cubic centimeters per minute.
- the flow rate of the dermal filler through the distal end portion of the needle is described above as being regulated to a substantially constant value when the needle is moved within the body, in some embodiments, the flow rate of the dermal filler can be selectively varied during the injection process. In this manner, the user can produce a bead and/or set of beads of dermal filler within the skin having spatially varied volume.
- the method 10 can include optionally regulating a flow rate of the dermal filler through the distal end portion of the needle such that the flow rate is substantially zero at a first time after the needle has been moved and still remains in the skin, at 20 .
- the method 10 can include optionally stopping the flow of the dermal filler through the distal end portion of the needle after the needle has been moved within the skin.
- the distal end portion of the needle can then be moved while the flow rate of the dermal filler through the distal end portion of the needle is zero, at 22 .
- the flow rate of the dermal filler through the distal end portion of the needle can then be regulated such that the flow rate is increased greater than zero, at 24 .
- the user can produce a discontinuous bead and/or set of beads of dermal filler within the skin, as shown in FIG. 5 .
- the flow rate of the dermal filler through the distal end portion of the needle can be regulated such that at least one discrete bead from the set of beads has a volume of approximately 0.1 cubic centimeters or less. In other embodiments, the flow rate of the dermal filler through the distal end portion of the needle can be regulated such that at least one discrete bead from the set of beads has a volume of less than approximately 0.01 cubic centimeters or less. In some embodiments, the flow rate of the dermal filler through the distal end portion of the needle can be regulated to produce such a set of discontinuous beads in areas of the skin surrounding the eye.
- the flow rate of the dermal filler through the distal end portion of the needle can be regulated in any suitable manner.
- the flow rate of the dermal filler 118 through the distal end portion 122 of the needle 120 can be regulated by selectively controlling the energy from the energy source 150 to the medical injector 100 .
- the flow rate of the dermal filler 118 through the distal end portion 122 of the needle 120 can be regulated by mechanisms outside of the flow path of the dermal filler 118 .
- the flow rate of the dermal filler 118 through the distal end portion 122 of the needle 120 can be regulated via the actuator 153 .
- the user can repeatedly and/or controllably actuate the energy source 150 using the actuator 153 .
- the user can repeatedly toggle the actuator 153 to selectively couple the energy source 150 to and decouple the energy source 150 from the medicament injector 100 .
- the flow rate of the dermal filler can be regulated to produce a discontinuous bead and/or set of beads of dermal filler within the skin, as described above.
- the flow rate of the dermal filler 118 through the distal end portion 122 of the needle 120 can be regulated by selectively restricting the flow path of the dermal filler 118 within the medical injector 100 and/or the needle 120 .
- the flow rate of the dermal filler 118 through the distal end portion 122 of the needle 120 can be regulated by a valve within the medicament flow path.
- FIGS. 6 and 7 are schematic illustrations of a medical device 200 , according to an embodiment configured inject a medicament 218 .
- the medical device 200 includes a medicament container 210 , a needle 220 , an energy source 250 and a regulator 260 .
- the medicament container 210 includes a piston 214 movably disposed therein, such that the medicament container 210 is divided into a first portion 215 and a second portion 217 .
- the piston 214 can be disposed within the medicament container 210 such that the first portion 215 of the medicament container 210 is fluidically isolated from the second portion 217 of the medicament container 217 .
- the first portion 215 of the medicament container 210 is configured to contain a medicament 218 having a high viscosity (i.e., a medicament having a viscosity of at least 100 Poise).
- the medicament 218 can be any medicament suitable for being injected into a body.
- the medicament 218 can be a high viscosity dermal filler (e.g., a liquid dermal filler, a paste-like dermal filler, a dermal filler including both a liquid component and a solid component, or the like).
- the medicament 218 can have a viscosity of at least 1000 Poise (100 N-sec/m 2 ).
- the medicament 218 can have a viscosity of at least 10,000 Poise.
- the medicament 218 can have a viscosity of at least 100,000 Poise.
- the medicament 218 can be a fluid that is characterized by a substantially linear shear stress as a function of the rate of shear strain applied thereto. Said another way, in some embodiments, the medicament 218 can be a Newtonian fluid having a viscosity that varies substantially only as a function of its temperature and pressure. In other embodiments, the medicament 218 can be a fluid that is characterized by a non-linear shear stress as a function of the rate of shear strain applied thereto.
- the medicament 218 can be a non-Newtonian fluid having a viscosity that varies according other factors, such as, for example, the magnitude of and/or rate of increase of a force applied to the medicament 218 .
- the needle 220 is coupled to the medicament container 210 such that the needle 220 is in fluid communication with the first portion 215 of the medicament container 210 .
- the needle 220 can be coupled to the medicament container 210 by any suitable mechanism.
- the needle 220 can be coupled to the medicament container 210 by a Luer fitting that provides a substantially fluid-tight seal (i.e., a seal that that substantially prevents a liquid and/or a gas from passing therethrough) between the needle 220 and the medicament container 210 .
- the fluid-tight seal can be a hermetic seal (i.e., a seal that substantially prevents a gas from passing therethrough).
- the needle 220 can have any suitable bore size and length.
- the needle can have a small bore to reduce patient discomfort during a procedure.
- the needle 220 can define a lumen having a nominal inner diameter of less than or equal to approximately 0.191 millimeters (i.e., a 27 gauge needle).
- the needle 220 can define a lumen having a nominal inner diameter of less than or equal to approximately 0.140 millimeters (i.e., a 30 gauge needle).
- the needle 220 can define a lumen having a nominal inner diameter of approximately 0.114 millimeters (i.e., a 31 gauge needle).
- the needle 220 can define a lumen having a nominal inner diameter of approximately 0.089 millimeters (i.e., a 32 gauge needle). In some embodiments, the needle 220 can have a length of at least 17 millimeters.
- the medicament 218 is conveyed from the first portion 215 of the medicament container 210 .
- a user can inject the medicament 218 into a body by actuating the medical device 200 to cause the piston 214 to move distally within the medicament container 210 .
- the energy source 250 is operatively coupled to the piston 214 such that the piston 214 can be moved non-manually.
- the energy source 250 can be any suitable form of energy configured produce kinetic energy to move the piston 214 within the medicament container 210 .
- the amount of kinetic energy required to move the piston 214 within the medicament container 210 is dependent on, among other things, the viscosity of the medicament 218 , the desired flow rate of the medicament 218 through the distal end portion 222 of the needle 220 , the length of the needle 220 and/or the size of the lumen defined by the needle 220 .
- the energy source 250 can produce kinetic energy sufficient to move the piston 214 such that a medicament 218 having a viscosity of at least 1000 Poise can be injected through the distal end portion 222 of the needle at a flow rate of at least 0.02 cubic centimeters per minute.
- the energy source 250 can produce kinetic energy sufficient to move the piston 214 such that a medicament 218 having a viscosity of at least 1000 Poise can be injected through the distal end portion 222 of the needle at a flow rate of at least 0.5 cubic centimeters per minute. In yet other embodiments, the energy source 250 can produce kinetic energy sufficient to move the piston 214 such that a medicament 218 having a viscosity of at least 10,000 Poise can be injected through the distal end portion 222 of the needle 220 at a flow rate of at least 0.5 cubic centimeters per minute.
- the energy source 250 can produce kinetic energy sufficient to move the piston 214 such that a medicament 218 having a viscosity of at least 10,000 Poise can be injected through the distal end portion 222 of the needle 220 at a flow rate of at least 3 cubic centimeters per minute. In still other embodiments, the energy source 250 can produce kinetic energy sufficient to move the piston 214 such that a medicament 218 having a viscosity of at least 10,000 Poise can be injected through the distal end portion 222 of the needle 220 at a flow rate of between 3 and 5 cubic centimeters per minute.
- the pressure of the medicament 218 within the medicament container 210 during an injection event is related to the kinetic energy applied to the piston 214 , and is therefore also dependent on, among other things, the viscosity of the medicament 218 , the desired flow rate of the medicament 218 through the distal end portion 222 of the needle 220 , the length of the needle 220 and/or the size of the lumen defined by the needle 220 .
- the pressure of the medicament 218 within the medicament container 210 can be modeled by the Hagen-Poiseuille law, as indicated below:
- P is the pressure of the medicament 218 within the medicament container
- ⁇ is the viscosity of the medicament 218
- L is the length of the needle 220
- Q is the flow rate of the medicament 218 through the distal end portion 222 of the needle 220
- R is the radius of the lumen defined by the needle 220 .
- the energy source 250 can be configured to move the piston 214 within the medicament container 210 such that a pressure of the medicament 218 within the medicament container 210 is greater than 345 kilopascals (50 p.s.i.). In other embodiments, the energy source 250 can be configured to move the piston 214 within the medicament container 210 such that a pressure of the medicament 218 within the medicament container 210 is greater than 690 kilopascals (100 p.s.i.). In still other embodiments, the energy source 250 can be configured to move the piston 214 within the medicament container 210 such that a pressure of the medicament 218 within the medicament container 210 is greater than 1035 kilopascals (150 p.s.i.). In still other embodiments, the energy source 250 can be configured to move the piston 214 within the medicament container 210 such that a pressure of the medicament 218 within the medicament container 210 is greater than 34.5 Megapascals (5000 p.s.i.).
- the regulator 260 is configured to regulate the flow rate of the medicament 218 through the distal end portion 222 of the needle 220 . In this manner, the user can adjust the flow rate of the medicament 218 through the distal end portion 222 of the needle 220 . In some embodiments, for example, the regulator 260 can substantially stop the flow of the medicament 218 through the distal end portion 222 of the needle 220 . In this manner, as described above, the user can discontinuously inject the medicament 218 within the body.
- the regulator 260 can be any suitable mechanism for regulating the flow rate of the medicament 218 through the distal end portion 222 of the needle 220 . As described above, in some embodiments, the regulator 260 can control the transmission of energy from the energy source 250 to the piston 214 . In other embodiments, the regulator 260 can selectively restrict the flow path of the medicament 218 within the first portion 215 of the medicament container 210 and/or the needle 220 .
- FIGS. 8-10 show a system 300 that employs a pressurized fluid to inject a dermal filler according to an embodiment.
- the system 300 includes a medicament container 310 , a needle (not shown in FIG. 8 ), a source of pressurized fluid 351 (see FIGS. 9 and 10 ), a regulator 360 (see FIGS. 9 and 10 ), and an adapter 330 configured to couple the medicament container 310 to the source of pressurized fluid 351 .
- the medicament container 310 is a substantially rigid container having a proximal end portion 311 and a distal end portion 312 .
- the medicament container 310 includes a piston 314 movably disposed therein such that the medicament container 310 is divided into a first portion 315 and a second portion 317 .
- the first portion 315 of the medicament container 310 is configured to contain a dermal filler 318 having a high viscosity.
- the medicament 318 can be any medicament suitable for being injected into a body, as described
- a coupler 325 is disposed at the distal end portion 312 of the medicament container 310 .
- the coupler 325 is configured to removably couple the needle (not shown in FIG. 8 ) to the distal end portion 312 of the medicament container 310 such that the needle is in fluid communication with the first portion 315 of the medicament container 310 .
- the coupler 325 can include any suitable coupling mechanism configured to produce a substantially fluid-tight coupling between the needle and the medicament container 310 .
- the coupler 325 can be a Luer lock fitting that threadedly engages a hub of the needle and maintains the hub in position about a protrusion (not shown in FIG. 8 ) at the distal end portion 312 of the medicament container 310 .
- the protrusion and the needle hub can have mating tapered surfaces such that a substantially fluid-tight interface is produced when the needle hub is coupled to the medicament container 310 by the coupler 325 .
- the adapter 330 which is configured to couple the medicament container 310 to the source of pressurized fluid 351 , includes a tube 342 and a coupler 343 .
- the tube 342 includes a proximal end portion 347 and a distal end portion 348 .
- the distal end portion 348 of the tube 342 is disposed about a barbed fitting 313 of the medicament container 310 to couple the medicament container 310 to the adapter 330 .
- the distal end portion 348 of the tube 342 can be secured about the barbed fitting 313 , for example, by the elastic properties of the tube 342 (i.e., an interference fit between the tube 342 and the barbed fitting 313 ), an external clamp (not shown), an adhesive, and/or the like.
- the coupler 343 is coupled to the proximal end portion 347 of the tube 342 , and is configured to couple the tube 342 to the source of pressurized fluid 351 , as described in more detail below.
- the source of pressurized fluid 351 and the regulator 360 are contained within the housing 354 .
- the source of pressurized fluid 351 can include any suitable fluid (e.g., a gas or a liquid) configured to produce a pressure when conveyed to the second portion 317 of the medicament container 310 , as described in more detail below.
- the source of pressurized fluid 351 can be a compressed CO 2 cartridge configured to be threadedly coupled to the housing 354 .
- the source of pressurized fluid 351 can include a reservoir, an accumulator and/or an adapter configured to receive a pressurized gas from an external source (i.e., a facility gas supply system).
- the housing 354 includes an actuator 353 , a coupler fitting 355 and a regulator knob 361 .
- the coupler fitting 355 is configured to receive the coupler 343 of the adapter 330 such that the proximal end portion 347 of the tube 342 can be removably coupled to the housing 354 .
- the medicament container 310 can be coupled to the source of pressurized fluid 351 .
- the piston 314 can be operatively coupled to the source of pressurized fluid 351 .
- the second portion 317 of the medicament container 310 can be placed in a fluidic circuit with the source of pressurized fluid 351 such that the second portion 317 of the medicament container 310 can be selectively placed in fluid communication with the source of pressurized fluid 351 .
- the actuator 353 which can be, for example, a push button actuator, is configured to selectively place the second portion 317 of the medicament container 310 in fluid communication with the source of pressurized fluid 351 . Similarly stated, the actuator 353 can selectively limit the flow rate and/or the pressure of the pressurized fluid delivered from the source of pressurized fluid 351 to the second portion 317 of the medicament container 310 . In this manner, the user can actuate the actuator 353 to initiate the non-manual injection of the dermal filler 318 from the medicament container 310 through the needle (not shown in FIG. 8 ).
- the dermal filler 318 is conveyed from the medicament container 310 non-manually, the user is not burdened with producing the energy and/or force necessary to cause the dermal filler 318 to be conveyed at the desired flow rate.
- This arrangement can result in a repeatable, continuous and/or controlled injection of the dermal filler 318 .
- the actuator 353 is shown as being actuated by a push button disposed on the housing 354 , in other embodiments, the actuator 353 can be actuated via a foot switch (not shown in FIGS. 9 and 10 ) coupled to the housing 354 .
- the user can initiate the injection of the dermal filler 318 in a “hands free” manner, thereby allowing the user to use their hands to control the placement and/or the movement of the needle within the body.
- the foot switch can be any suitable switch configured to cause the actuator 353 to selectively place the second portion 317 of the medicament container 310 in fluid communication with the source of pressurized fluid 351 .
- the foot switch can be, for example, an electronic switch, a pneumatic switch or the like.
- the foot switch can be wirelessly coupled to the actuator 353 .
- the regulator knob 361 can be used to adjust the regulator 360 to selectively regulate the flow rate and/or the pressure of the pressurized fluid delivered from the source of pressurized fluid 351 to the second portion 317 of the medicament container 310 when the actuator 353 is actuated. In this manner, the flow rate of the dermal filler 318 from the medicament container 310 can be regulated. This arrangement allows the flow rate of the dermal filler 318 to be regulated without affecting the flow path of the dermal filler 318 and/or without any portion of the regulator 360 contacting the dermal filler 318 .
- the regulator 360 can be any suitable mechanism configured to regulate the flow rate and/or the pressure of the pressurized fluid from the source of pressurized fluid 351 .
- the regulator 360 include components from an EFD® dispensing system, such as, for example, the EFD® 2400 pneumatic dispenser or the EFD® 2800 hydraulic controller manufactured by EFD, Inc. (a Nordson Company).
- a kit can include the adapter 330 and one or more medicament containers 310 pre-filled with the dermal filler 318 .
- a kit can include multiple medicament containers 310 pre-filled with different volumes of the dermal filler 318 . In this manner, the user can select from among the pre-filled medicament containers 310 based on the amount of dermal filler 318 to be injected (e.g., the amount of dermal filler necessary for the desired cosmetic and/or therapeutic result).
- a kit can include pre-filled medicament containers 310 containing approximately 1 cubic centimeter, 2 cubic centimeters, 3 cubic centimeters, 5 cubic centimeters and/or 10 cubic centimeters of dermal filler 318 .
- a kit can include pre-filled medicament containers 310 containing greater than 10 cubic centimeters of dermal filler 318 .
- Such pre-filled medicament containers can accommodate increased volume of the dermal filler 318 by having an increased length and/or an increased inner diameter. Because the dermal filler 318 is injected non-manually, as described above, the length and/or the inner diameter of the medicament container 310 can be varied without regard to the physical limitations associated with actuating the medicament container manually. More particularly, because the dermal filler 318 is injected non-manually, the length and/or the inner diameter of the medicament container 310 can be varied independently from the distance through which an average user can manually depress a plunger and/or the force that an average user can apply when manually depressing a plunger.
- some known medical injectors are limited in the volume of dermal filler that can be contained therein because of the physical constraints imposed by manually actuating the medical injector. More particularly, some known medical injectors are configured contain a maximum of approximately 1 cubic centimeter of dermal filler. In such known manually-actuated injectors, the medicament pressure during injection is inversely proportional to the square of the inner diameter. Thus, increasing the size of the inner diameter to allow a greater volume of dermal filler to be contained within the medical injector can result in an increase in the force required to generate the desired medicament pressure. Accordingly, because the force that can be applied manually by a user is limited, increasing the size of the inner diameter is often not desirable.
- the length of travel of the piston within the medicament container i.e., the stroke of the injector
- the length of travel of the piston within the medicament container can be increased to allow a greater volume of dermal filler to be contained within the medical injector.
- the distance through which the piston can be moved is also limited based on the size of the user's hand.
- an adapter can be coupled to a medicament container having a flange. In this manner, the adapter can be configured to receive a flanged syringe.
- FIG. 11 shows a portion of a system 400 that employs a pressurized fluid to inject a dermal filler according to an embodiment.
- the system 400 includes a medicament container 410 , a needle (not shown in FIG. 11 ), a source of pressurized fluid (not shown in FIG. 11 ), and an adapter 430 configured to couple the medicament container 410 to the source of pressurized fluid.
- the source of pressurized fluid can be similar to the source of pressurized fluid 351 shown and described above. Additionally, the system 400 can include a regulator similar to regulator 360 shown and described above, and an actuator similar to the actuator 353 shown and described above. Accordingly, only the medicament container 410 and the adapter 430 are discussed in detail below.
- the medicament container 410 which can be, for example, a commercially-available syringe, has a proximal end portion 411 and a distal end portion 412 .
- the medicament container 410 includes a piston 414 movably disposed therein such that the medicament container 410 is divided into a first portion 415 and a second portion 417 .
- the first portion 415 of the medicament container 410 is configured to contain a dermal filler 418 having a high viscosity.
- the medicament 418 can be any medicament suitable for being injected into a body, as described herein.
- a coupler 425 is disposed at the distal end portion 412 of the medicament container 410 . As described above, the coupler 425 is configured to removably couple the needle (not shown in FIG. 11 ) to the distal end portion 412 of the medicament container 410 .
- the adapter 430 which is configured to couple the medicament container 410 to the source of pressurized fluid, includes a hand piece 449 , a tube 442 and a coupler 443 .
- the hand piece 449 includes a proximal end portion 431 , a distal end portion 432 , and an outer surface that can be contoured to assist the user in gripping and/or manipulating the hand piece 449 .
- the distal end portion 432 of the hand piece 449 includes a coupler 433 configured to removably couple the hand piece 449 to the medicament container 410 . More particularly, the coupler 433 is configured to couple the hand piece 449 to a standard, commercially-available syringe. In this manner, the adapter 430 can be used on a variety of different medicament containers 410 .
- the coupler 433 includes a protrusion 434 , a sealing member 435 , and two coupling members 436 .
- the protrusion 434 is configured to be disposed within the second portion 417 of the medicament container 410 when the coupler 433 is coupled to the medicament container 410 .
- the sealing member 435 is disposed about the protrusion 434 and forms a substantially fluid-tight seal between the protrusion 434 and the inner surface of the medicament container 410 when the coupler 433 is coupled to the medicament container 410 .
- the sealing member 435 can be, for example, an o-ring, and can be constructed from any suitable material that is compatible with the medicament 418 and/or the pressurized fluid from the source of pressurized fluid.
- each coupling member 436 includes a protrusion 437 that defines a channel within which the flange 413 of the medicament container 410 is received when the coupler 433 is coupled to the medicament container 410 .
- each coupling members 436 is configured to bend outwardly, as shown by the arrow EE, when pressed against the flange 413 to allow the flange 413 be disposed within the channel.
- the coupling members move back to their respective relaxed positions such that the flange 413 and the coupling members 436 cooperatively limit the axial movement of the medicament container 410 relative to the hand piece 449 .
- the tube 442 includes a proximal end portion 447 and a distal end portion 448 .
- the distal end portion 448 of the tube 442 is coupled to the barbed fitting at the proximal end portion 431 of the hand piece 449 .
- the distal end portion 448 of the tube 442 can be secured about the barbed fitting, for example, by the elastic properties of the tube 442 (i.e., an interference fit between the tube 442 and the barbed fitting), an external clamp (not shown), an adhesive, and/or the like.
- the coupler 443 is coupled to the proximal end portion 447 of the tube 442 , and is configured to couple the tube 442 to the source of pressurized fluid, as described above.
- an adapter and/or a hand piece can be configured to indirectly couple a medicament container and/or a piston to a source of pressurized fluid.
- an adapter and/or a hand piece can be configured to convert and/or amplify the pressure produced by the source of pressurized fluid to move a piston with sufficient force to generate the desired medicament flow rates and/or medicament pressure.
- FIG. 12 shows a portion of a system 500 that employs a pressurized fluid to inject a dermal filler according to an embodiment.
- the system 500 includes a medicament container 510 , a needle 520 , a source of pressurized fluid (not shown in FIG. 12 ), and an adapter 530 configured to couple the medicament container 510 to the source of pressurized fluid.
- the source of pressurized fluid can be similar to the source of pressurized fluid 351 shown and described above.
- the system 500 can include a regulator similar to regulator 360 shown and described above, and an actuator similar to the actuator 353 shown and described above. Accordingly, only the adapter 530 and the medicament container 510 are discussed below.
- the medicament container 510 has a proximal end portion 511 and a distal end portion 512 .
- the distal end portion 512 is coupled to the needle 520 , as discussed above.
- the proximal end portion 511 is coupled to the adapter 530 , as discussed below.
- the medicament container 510 includes a first piston 514 movably disposed therein.
- the first piston 514 has a diameter d 1 .
- the adapter 530 includes a hand piece 549 , a tube 542 and a coupler 543 .
- the tube 542 includes a proximal end portion 547 and a distal end portion 548 .
- the distal end portion 548 of the tube 542 is coupled to the proximal end portion 531 of the hand piece 549 .
- the coupler 543 is coupled to the proximal end portion 547 of the tube 542 , and is configured to couple the tube 542 to the source of pressurized fluid, as described above. In this manner, a pressurized fluid can be conveyed from the source of pressurized fluid into the hand piece 549 , as described below.
- the hand piece 549 includes a proximal end portion 531 and a distal end portion 532 .
- the distal end portion 532 of the hand piece 549 includes a coupler 533 configured to removably couple the hand piece 549 to the medicament container 510 .
- the coupler 533 includes two coupling members 536 that are disposed approximately equidistance circumferentially about the coupler 533 . Said another way, the coupling members 536 are disposed approximately 180 degrees apart. In this manner the coupling members 536 engage the flange 513 of the medicament container 510 at two distinct circumferential locations when the coupler 533 is coupled to the medicament container 510 .
- the hand piece 549 defines a lumen 544 , within which a second piston 546 , having a diameter d 2 , and a push rod 545 are movably disposed.
- the second piston 546 is coupled to the first piston 514 by the push rod 545 .
- a force acting on the second piston 546 is transferred directly to the first piston 514 .
- the force exerted by the pressurized fluid on the second piston 546 is transferred to the first piston 514 .
- equations (2) and (3) can be rearranged to define the relationship between the pressure P 2 of the pressurized fluid and the pressure P 1 of the dermal filler:
- the delivery pressure P 1 of the dermal filler in the medicament container can be controlled by controlling the pressure P 2 of the pressurized fluid in the hand piece 549 and/or by adjusting the area ratio (also referred to as the amplification factor) of the second piston 546 and the first piston 514 .
- the hand piece 549 can amplify the pressure of the pressurized fluid.
- the hand piece 549 can be configured to produce any desired amount of pressure amplification.
- the first piston 514 can have a diameter d 1 (i.e., the inner diameter of the medicament container 510 ) of approximately 5 mm (0.20 inches), and the second piston 546 can have a diameter d 2 of approximately 22 mm (0.88 inches).
- the amplification factor is approximately 19.3. Accordingly, a pressure within the hand piece 549 of approximately 890 kPa (130 p.s.i.) will result in a pressure within the medicament container of approximately 17.2 MPa (2500 p.s.i.).
- the first piston 514 it is desirable for the first piston 514 to have a diameter greater than 5 mm.
- the medicament container 510 is configured to contain approximately 2 cubic centimeters of dermal filler, and therefore has an inner diameter of approximately 7 mm (0.28 inches).
- the second piston 546 can have a diameter d 2 of approximately 22 mm (0.88 inches), resulting in an amplification factor of approximately 9.9. Accordingly, a pressure within the hand piece 549 of approximately 690 kPa (100 p.s.i.) will result in a pressure within the medicament container of approximately 6.9 MPa (1000 p.s.i.).
- the second piston 546 it is desirable for the second piston 546 to have a diameter less than 22 mm, for example, to provide improved maneuverability during use.
- the medicament container 510 is configured to contain approximately 2 cubic centimeters of dermal filler, and has an inner diameter of approximately 7 mm (0.28 inches).
- the second piston 546 can have a diameter d 2 of approximately 15.7 mm (0.62 inches), resulting in an amplification factor of approximately 5. Accordingly, a pressure within the hand piece 549 of approximately 690 kPa (100 p.s.i.) will result in a pressure within the medicament container of approximately 3.5 MPa (500 p.s.i.).
- an adapter can be coupled to a medicament container in any suitable manner.
- an adapter can be coupled to a medicament container by three, four, or more coupling members. In this manner, the medicament container can be securely fastened to the adapter to withstand the high pressures (and therefore the resulting forces) that can be applied during use.
- an adapter can be coupled to a medicament container by a nut configured to engage a flange of the medicament container substantially around the entire circumference of the flange. For example, FIG.
- FIG. 13 shows a portion of a system 600 that employs a pressurized fluid to inject a dermal filler according to an embodiment.
- the system 600 includes a medicament container 610 , a needle 620 , a source of pressurized fluid (not shown in FIG. 13 ), and an adapter 630 configured to couple the medicament container 610 to the source of pressurized fluid.
- the system 600 is similar in many respects to the system 500 described above, and is therefore not described in detail below.
- the system 600 differs, however, in that the adapter 630 is coupled to the medicament container 610 by a coupling nut 639 .
- the coupling nut 639 is disposed about the proximal end portion 611 of the medicament container 610 such that a shoulder (not shown) of the coupling nut 639 engages the flange (not shown) of the medicament container 610 .
- the coupling nut 639 is configured to be threadedly coupled to the distal end portion 632 of the hand piece 649 . In this manner, when the coupling nut 639 is tightened on to the hand piece 649 , the shoulder of the coupling nut 639 exerts a coupling force around the circumference of the flange of the medicament container 610 .
- a regulator can regulate the flow rate of dermal filler by obstructing and/or modifying a flow path of the dermal filler.
- a regulator can have at least a portion disposed within the flow path of the dermal filler.
- FIGS. 14-17 show a system 600 that includes a self-contained source of pressurized gas to inject a dermal filler according to an embodiment.
- the system 700 includes a medicament container 710 , a needle 720 , a source of pressurized fluid 750 , and an adapter 730 configured to couple the medicament container 710 to the source of pressurized fluid.
- the medicament container 710 has a proximal end portion 711 and a distal end portion 712 .
- the medicament container 710 includes a first piston 714 movably disposed therein.
- the first piston 714 has a diameter d 1 .
- the medicament container 710 is configured to contain a dermal filler having a high viscosity.
- the regulator 760 is disposed at the distal end portion 712 of the medicament container 710 .
- a coupler 725 is attached to the regulator and is configured to removably couple the needle 720 to the regulator, and thus to the distal end portion 712 of the medicament container 710 .
- the coupler 725 can be any suitable coupler, as described above.
- the distal end portion 712 of the medicament container 710 includes a flange 713 that can be coupled to the adapter 730 , as described below.
- the adapter 730 includes a proximal end portion 731 and a distal end portion 732 .
- the distal end portion 732 of the adapter 730 includes a coupler 733 configured to removably couple the adapter 730 to the medicament container 710 .
- the coupler 733 includes two coupling members 736 that are disposed approximately equidistance circumferentially about the coupler 733 . Said another way, the coupling members 736 are disposed approximately 180 degrees apart. In this manner the coupling members 736 engage the flange 713 of the medicament container 710 at two distinct circumferential locations when the coupler 733 is coupled to the medicament container 710 .
- the adapter 730 defines a lumen 744 , within which a second piston 746 , having a diameter d 2 , and a push rod 745 are movably disposed.
- a second piston 746 having a diameter d 2
- a push rod 745 are movably disposed.
- the adapter 730 is configured to amplify the pressure of the pressurized fluid from the source of pressurized fluid 750 .
- diameter d 1 of the first piston 714 can be approximately 7 mm (0.28 inches) and the diameter d 2 of the second piston 746 can be approximately 12.7 mm (0.5 inches).
- the pressure provided by the source of pressurized fluid 750 is approximately 534 kPa (76 p.s.i.)
- the pressure of the dermal filler within the medicament container 710 is approximately 1.7 MPa (250 p.s.i.).
- the outer surface of the adapter 730 defines an opening 727 in fluid communication with the lumen 744 .
- the opening 727 is positioned towards a distal end portion 732 of the adapter 730 , and is configured to allow fluid within the lumen 744 distally of the second piston 746 to evacuate from the adapter 730 when the second piston 746 moves distally within the adapter 730 .
- the opening 727 can include a membrane configured to allow fluids to move through the opening in only one direction. In other embodiments, the opening 727 can be configured to allow fluids to flow freely therethrough in any direction.
- the source of pressurized fluid 750 is movably coupled to the proximal end portion 731 of the adapter 730 . More particularly, the source of pressurized fluid 750 can be actuated by moving the source of pressurized fluid 750 relative to the adapter 730 . In this manner, a valve (not shown in FIG. 14 ) can be opened thereby releasing pressurized fluid from the source of pressurized fluid 750 into the lumen 744 of the adapter 730 . In some embodiments, for example, a release valve (not shown in FIG. 14 ) can be actuated when the source of pressurized fluid 750 is moved relative to the adapter 730 , thereby releasing a pressurized fluid into the lumen 744 of the adapter.
- the source of pressurized fluid 750 can be any suitable source of pressurized fluid, including those described in U.S. Provisional Application Ser. No. 61/016,223, entitled “Self-Contained Pressurized Injection Device,” filed Dec. 21, 2007, which is incorporated herein by reference in its entirety.
- the regulator 760 includes a regulator body 761 , a valve member 770 , a valve actuator 780 , and a valve seat 790 .
- the valve actuator 780 includes a lever 781 and two elongated members 782 .
- Each of the elongated members 782 includes a protrusion 783 , which can be disposed within the regulator body 761 (see e.g., FIG. 17 ). In this manner, when lever 781 of the valve actuator 780 is moved, the valve actuator 780 can pivot about the protrusions 783 .
- the regulator body 761 includes a proximal end portion 762 and a distal end portion 763 , and defines a lumen 764 therethrough.
- the side wall of the regulator body 761 defines openings 765 within which a portion of the actuator 780 can be disposed, as described in more detail herein.
- the distal end portion 763 of the regulator body 761 includes a stem 766 , a portion of which is disposed within the hub 724 of the needle 720 .
- the coupler 725 is attached to the stem 766 , and is configured to removably couple the needle 720 to the regulator 760 .
- the proximal end portion 762 of the regulator body 761 is disposed about and coupled to the distal end portion 712 of the medicament container 710 .
- the proximal end portion 762 of the regulator body 761 can be coupled to the distal end portion 712 of the medicament container 710 by any suitable means, such as, for example, an adhesive, a crimped fit, an external clamp or
- a mounting ring 795 is disposed between the proximal end portion 762 of the regulator body 761 and the distal end portion 712 of the medicament container 710 to provide a substantially fluid-tight seal between the regulator body 761 and the medicament container 710 .
- the valve seat 790 is coupled to the mounting ring 795 such that a seat surface 792 is disposed within the medicament container 710 facing in a proximal direction. In this manner, the mounting ring 795 can position the valve seat 790 relative to the regulator body 761 and/or the valve member 770 .
- the valve member 770 includes a proximal end portion 771 and a distal end portion 772 , and defines a lumen 777 .
- the distal end portion 772 of the valve member 770 includes a shoulder 779 , a seal 774 , and defines an actuation groove 775 .
- the seal 774 is configured to engage an inner surface of the regulator body 761 to form a substantially fluid-tight seal between the valve member 770 and the regulator body 761 .
- the actuation groove 775 is configured to receive a portion of each elongated member 782 of the valve actuator 780 .
- valve member 770 moves longitudinally within the regulator body 761 .
- the proximal end portion 771 of the valve member 770 includes a head 778 and defines openings 776 .
- the openings 776 extend through the side wall of the valve member 770 and are in fluid communication with the lumen 777 of the valve member 770 .
- the valve member 770 is movably disposed within the lumen 764 of the valve body 761 between a first position (e.g., a closed position, as shown in FIG. 17 ), a second position (e.g., a fully opened position, not shown in FIGS. 14-17 ), and any number of positions therebetween. In this manner, the regulator 760 can regulate the flow rate of dermal filler from the medicament container 710 through the needle 720 .
- the head 778 of the valve member 770 is disposed against the seat surface 792 of the valve seat 790 to form a substantially fluid-tight seal, as shown in FIG. 17 .
- the valve member 770 when the valve member 770 is in the first position, the dermal filler cannot flow from the medicament container 710 through the needle 720 . Said another way, when the valve member 770 is in the first position, the flow rate of the dermal filler from the medicament container 710 is substantially zero. Moreover, because the pressure within the medicament container 710 produces a force on the head 778 in a distal direction, the pressure within the medicament container tends to maintain the valve member 770 in the first position. Additionally, as shown in FIG. 17 , when the valve member 770 is in the first position, the shoulder 779 of the valve member 770 is disposed against a distal portion of the valve seat 790 . In this manner, the valve member 770 is maintained in the first position by the force of the valve seat 790 on the shoulder 779 .
- the user can move the lever 781 of the valve actuator 780 inward, as shown by the arrow FF in FIG. 17 .
- the inward movement of the lever 781 causes the valve actuator 780 to pivot about the protrusions 783 .
- the elongated members 782 of the valve actuator 780 move proximally.
- a portion of each of the elongate members 782 is disposed within the actuation groove 775 of the valve member 770 . Accordingly, proximal movement of the elongated members 782 causes the valve member 770 to move proximally, as shown by the arrow GG in FIG. 17 .
- the proximal movement of the valve member 770 causes the head 778 to be spaced apart from the seat surface 792 , thereby allowing flow of the dermal filler through the openings 776 and into the lumen 777 of the valve member 770 . Said another way, the proximal movement of the valve member 770 causes the head 778 to be spaced apart from the seat surface 792 , thereby defining a medicament flow path (as shown by the dashed line in FIG. 17 ).
- the shoulder 779 exerts a force on the distal portion of the valve seat 790 , thereby causing the distal portion of the valve seat 790 to deform.
- the distal portion valve seat 790 acts as a biasing member to urge the valve member 770 towards the first position.
- a medicament and/or dermal filler can include a pain reliever, such as, for example, lidocaine.
- a medicament and/or dermal filler can include a colorant and/or a marker.
- a medicament and/or dermal filler can include a radio-opaque marker.
- a medicament and/or dermal filler can include a tattoo ink.
- a dermal filler can include, for example, a side chain crystalline (SCC) polymer of the type disclosed in International Patent Application No. PCT/US2007/023226, entitled “Compositions, Devices and Methods for Modifying Soft Tissue,” which is incorporated herein by reference in its entirety.
- a dermal filler can include hyaluronic acid.
- a dermal filler can include polyacrylamide, collagen (either human and/or bovine), polymethylmethacrylate, silicone, calcium hydroxylapatite (CaHA), hydrophilic polyacrylamid gel (PAAG), and/or poly-L-lactic acid hydrogel (PLLA).
- a dermal filler can include any of the following commercially-available dermal fillers: PuragenTM and its derivatives, produced by Mentor Corporation, Belotero® and its derivatives, produced by Merz Pharmaceuticals, BIO-ALCAMIDTM and its derivatives, produced by Polymekon S.R.L., Outline® and its derivatives, produced by ProCytech, HylaNew® and its derivatives, produced by Prollenium Medical Technologies, Inc., Restylane® and its derivatives, produced by Q-Med or Medicis Pharmaceutical Corporation, Reviderm USA and its derivatives, produced by Rofil Medical International N.V., Teosyal® and its derivatives, produced by Teoxane Laboratories, Fascian® and its derivatives, produced by Fascia Biosystems, LLC, FG-5017 and its derivatives, produced by Fibrogen, Inc., Amazingel and its derivatives, produced by FuHua High Molecular Matter Company, Ltd., Laresse® Dermal Filler and its derivatives, produced by FuHua
- an energy source can include any suitable form of stored energy and/or a mechanism configured to convert energy from one form to another.
- an energy source can include a source of stored electrical energy (e.g., a battery), a source of chemical energy (e.g., products that react to produce energy), and/or a source of mechanical energy (e.g., a spring).
- an energy source can include a mechanism configured to convert electrical potential energy to a kinetic energy.
- an energy source can include an electric motor (e.g., a stepper motor) configured to receive electrical energy (from a battery or from an AC power source) and convert the electrical energy into a kinetic energy to move a piston.
- a medicament container can be devoid of a piston.
- a fluid powered injection system can include a medicament container devoid of a piston, and include a source of pressurized fluid.
- the dermal filler contained within the medicament container can have a high viscosity such that it will not readily mix with the pressurized fluid. Accordingly, to actuate the injector, the pressurized fluid is conveyed into the medicament container and in direct contact with the dermal filler to be injected, thereby moving the dermal filler within the medicament container.
- the coupling members 436 are shown and described as being configured to bend outwardly when the coupler 433 is being coupled to the medicament container 410 , in other embodiments, the coupling members 436 can be substantially rigid.
- the flange 413 of the medicament container 410 does not extend circumferentially around the medicament container 410 , but rather there may be two flanges positioned on opposite sides of the medicament container 410 .
- the medicament container 410 can be rotated relative to the hand piece 449 until the flanges are out of alignment with the coupling members 436 .
- the hand piece 449 can then be disposed about the medicament container 410 .
- the medicament container 410 can then be rotated relative to the hand piece 449 until the flanges are aligned with the coupling members 436 , thereby securing the medicament container within the hand piece 449 .
- an apparatus in some embodiments, for example, includes a medicament container, a needle, an energy source, and a regulator.
- the medicament container has a piston movably disposed therein such that the medicament container is divided into a first portion and a second portion.
- the first portion of the medicament container is configured to contain a medicament, such as, for example a dermal filler.
- the needle is coupled to the medicament container such that the needle is in fluid communication with the first portion of the medicament container.
- the energy source is operatively coupled to the piston and is configured to produce a kinetic energy to move the piston within the medicament container such that the medicament having a viscosity of at least 1000 Poise (100 N-sec/m 2 ) can be conveyed from the first portion of the medicament container through a distal end of the needle at a flow rate of at least 0.02 cubic centimeters per minute.
- the regulator is configured to regulate the flow rate of the medicament through the distal end of the needle.
- an apparatus in some embodiments, for example, includes a medical injector, a pressurized fluid source, and a regulator.
- the medical injector is configured to contain a dermal filler, and includes a needle.
- the needle defines a lumen therethrough having a nominal inner diameter of less than approximately 0.140 millimeters (i.e., the needle is smaller than 30 gauge), and has a length of at least 17 millimeters.
- the pressurized fluid source which can include, for example, a canister of pressurized fluid, is operatively coupled to the medical injector.
- a pressurized fluid from the pressurized fluid source has a pressure of at least 345 kilopascals.
- the pressurized fluid is configured to actuate the medical injector such that the dermal filler can be conveyed from the medical injector through the lumen of the needle.
- the regulator is configured to regulate the flow rate of the dermal filler through the lumen of the needle.
- a medical device can include a remotely located source of pressurized fluid, such as the source of pressurized fluid 351 shown and described above, and a regulator coupled to the medicament container, such as the regulator 760 shown and described above.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Description
- This application is a continuation-in-part of International Patent Application No. PCT/US2007/023226, entitled “Compositions, Devices and Methods for Modifying Soft Tissue,” filed Nov. 1, 2007, which claims priority to U.S. Provisional Application Ser. No. 60/856,430, entitled “Soft Tissue Modification,” filed Nov. 3, 2006, U.S. Provisional Application Ser. No. 60/857,546, entitled “Soft Tissue Modification,” filed Nov. 8, 2006, and U.S. Provisional Application Ser. No. 60/857,755, entitled “Injection Device,” filed Nov. 8, 2006, each of which is incorporated herein by reference in its entirety.
- This application claims priority to U.S. Provisional Application Ser. No. 60/964,066, entitled “Controlled Injection Device,” filed Aug. 8, 2007, which is incorporated herein by reference in its entirety. This application claims priority to U.S. Provisional Application Ser. No. 60/993,541, entitled “Controlled Injection Device,” filed Sep. 12, 2007, which is incorporated herein by reference in its entirety. This application claims priority to U.S. Provisional Application Ser. No. 61/016,223, entitled “Self-Contained Pressurized Injection Device,” filed Dec. 21, 2007, which is incorporated herein by reference in its entirety.
- The invention relates generally to medical devices and methods, and more particularly to medical devices and methods for injecting high viscosity dermal fillers into a body.
- High viscosity medicaments, such as dermal fillers, can be injected into the body to augment soft tissue portions within the body. For example, high viscosity compositions can be injected adjacent the urinary sphincter muscle to increase the volume of the tissue within the urinary tract to treat urinary incontinence. High viscosity compositions can also be injected into the skin to change the contour of and/or increase the volume of the skin. For example, known high viscosity compositions can be injected within facial skin to remove wrinkles, treat scars or the like.
- Some known procedures for injecting high viscosity dermal fillers include injecting the dermal filler using a standard syringe. In such procedures, the force and/or pressure required to convey the dermal filler from the syringe body through the needle can be generated manually by having the user manually depress a plunger into the syringe body. The force generated by manually depressing a plunger, however, can be sporadic, thus resulting in undesirable fluctuations in the flow of the dermal filler through the needle, which can result in the user injecting more or less dermal filler at a particular location within the body than is desired. Generating the injection force and/or pressure manually can also result in inconsistent results between different users. Moreover, in certain situations, the force generated by manually depressing a plunger can be insufficient to provide the desired flow rate of dermal filler. Additionally, because the total volume of dermal filler injected is a function of the length of travel of the plunger, it can be difficult to deliver a sufficient volume of dermal filler when injecting the dermal filler manually using a standard syringe. Moreover, generating the injection force and/or pressure manually can result in user fatigue and/or chronic health problems for the user, such as, for example arthritis.
- Thus, a need exists for improved apparatus and methods for injecting high viscosity dermal fillers into a body.
- Medical injectors and methods of injecting high viscosity dermal fillers are described herein. In some embodiments, a method includes inserting a distal end portion of a needle of a medical injector into a skin of a body. An energy source operatively coupled to the medical injector is actuated such that a dermal filler is conveyed from the medical injector into the skin through the distal end portion of the needle. The distal end portion of the needle is moved within the skin during the actuating.
-
FIG. 1 is a flow chart illustrating a method of assembling a medical injector according to an embodiment. -
FIGS. 2-4 are schematic illustration showing a portion of a body B containing a dermal filler in a first configuration, a second configuration and a third configuration, respectively, according to the method illustrated inFIG. 1 . -
FIG. 5 is schematic illustration showing a portion of a body B containing a dermal filler injected therein by a method according to an embodiment. -
FIGS. 6 and 7 are schematic illustrations of a medical device according to an embodiment, in a first configuration and a second configuration, respectively. -
FIG. 8 is a side view of a portion of a system for injecting dermal fillers according to an embodiment. -
FIGS. 9 and 10 are perspective views of a portion of the system for injecting dermal fillers shown inFIG. 8 . -
FIG. 11 is a side view of a portion of a system for injecting dermal fillers according to an embodiment. -
FIG. 12 is a side view of a portion of a system for injecting dermal fillers including a pressure amplifier according to an embodiment. -
FIG. 13 is a perspective view of a portion of a system for injecting dermal fillers according to an embodiment. -
FIG. 14 is a perspective view of a system for injecting dermal fillers including a self-contained source of pressurized fluid according to an embodiment. -
FIG. 15 is a perspective view of a portion of the system for injecting dermal fillers shown inFIG. 14 . -
FIG. 16 is an exploded view of the portion of the system for injecting dermal fillers shown inFIG. 15 . -
FIG. 17 is a cross-sectional view of the portion of the system for injecting dermal fillers shown inFIG. 15 . - In some embodiments, a method includes inserting a distal end portion of a needle of a medical injector into a skin of a body. The skin can include, for example, facial skin. An energy source operatively coupled to the medical injector is actuated such that a dermal filler is conveyed from the medical injector into the skin through the distal end portion of the needle. The energy source can include, for example, a pressurized fluid configured to move a piston within the medical injector. The distal end portion of the needle is moved within the skin during the actuating. In some embodiments, a non-manually-powered machine operatively coupled to the medical injector is actuated such that a dermal filler is conveyed from the medical injector into the skin through the distal end portion of the needle. Optionally, the method can include regulating a flow rate of the dermal filler through the distal end portion of the needle during the actuating.
- As used herein, the words “proximal” and “distal” refer to direction closer to and away from, respectively, an operator (e.g., surgeon, physician, nurse, technician, etc.) of the medical device. Thus, for example, the end of the medicament delivery device contacting the patient's body would be the distal end of the medicament delivery device, while the end opposite the distal end would be the proximal end of the medicament delivery device.
- As used herein, the words “non-manual” or “non-manually” are used to describe an operation and/or an apparatus in which a source of energy and/or a force for carrying out the operation and/or a function of the apparatus is not directly produced by a human. For example, an apparatus for non-manually injecting a dermal filler can include any apparatus in which the force to inject the dermal filler is not directly produced by a human. Examples of a non-manual injection apparatus include an apparatus having a compressed gas source to provide the injection force, an apparatus having a spring to provide the injection force, and an apparatus having an electric motor to provide the injection force. An apparatus for non-manually injecting a dermal filler, however, can include a manual actuator (e.g., an on/off switch, a push button, a foot pedal or the like) to initiate the non-manual injection.
-
FIG. 1 is a flow chart illustrating amethod 10 of injecting a dermal filler according to an embodiment.FIGS. 2-4 are schematic illustrations showing a portion of a body B containing adermal filler 118 injected therein according to themethod 10, in a first configuration, a second configuration and a third configuration, respectively. As shown inFIG. 1 , the illustrated method includes inserting a distal end portion of a needle of a medical injector into a skin of a body, at 12. The skin can be disposed at any location of the body, such as for example, facial skin. Referring toFIG. 2 , thedistal end portion 122 of theneedle 120 is inserted into the skin SK in a distal direction as shown by the arrow AA. Theneedle 120 is inserted into the skin SK at an angle Θ relative to the surface of the skin SK and at depth d within the body B. Theneedle 120 can be inserted into the skin SK at any suitable angle Θ and at any suitable depth d for achieving the desired result. In some embodiments, for example, theneedle 120 is inserted into the skin SK at an angle Θ of between 5 and 35 degrees. In other embodiments, theneedle 120 is inserted into the skin SK at an angle Θ of approximately 20 degrees. In some embodiments, for example, theneedle 120 is inserted into the skin SK at a depth d of between 1.5 and 6 millimeters. In other embodiments, theneedle 120 is inserted into the skin SK at a depth d of between approximately 1.5 and 2 millimeters. - Although the
distal end portion 122 of theneedle 120 is shown as being inserted into the subcutaneous tissue S of the skin SK, in some embodiments, thedistal end portion 122 of theneedle 120 can be inserted into the epidermis E and/or the dermis D of the skin SK. In other embodiments, thedistal end portion 122 of theneedle 120 can be inserted below the subcutaneous tissue S. In yet other embodiments, thedistal end portion 122 of theneedle 120 can be inserted through the skin SK into another portion of the body B, such as for example a urinary sphincter (not shown inFIGS. 2-5 ). - Returning to the flow chart shown in
FIG. 1 , an energy source operatively coupled to the medical injector is actuated such that a dermal filler is conveyed from the medical injector into the skin through the distal end portion of the needle, at 14. As shown inFIG. 3 , theenergy source 150 is actuated via anactuator 153. Theenergy source 150 can include any suitable form of energy that can act upon themedical injector 100 to convey thedermal filler 118 from themedical injector 100 through thedistal end portion 122 of theneedle 120. For example, in some embodiments, theenergy source 150 can include a pressurized gas that exerts a force on a portion of themedical injector 100. When theenergy source 150 is actuated by theactuator 153, thedermal filler 118 is conveyed from themedical injector 100 through thedistal end portion 122 of theneedle 120. In this manner, thedermal filler 118 can be injected into the body B non-manually. Said another way, thedermal filler 118 can be injected into the body B without the user producing the energy necessary for the injection. - Returning to the flow chart shown in
FIG. 1 , the distal end portion of the needle is moved within the skin when the energy source is being actuated, at 16. In this manner, the user can vary the location of the distal end portion of the needle within the skin when the dermal filler is being injected into the body B. As shown inFIG. 4 , thedistal end portion 122 of theneedle 120 is moved in a proximal direction, as shown by the arrow BB, when theenergy source 150 is being actuated. In this manner, the user can inject a substantially continuous bead ofdermal filler 118 along a desired passageway (e.g., a wrinkle) within the skin SK. More particularly, thedistal end portion 122 of theneedle 120 is moved in a direction substantially opposite the direction of flow of thedermal filler 118 from thedistal end portion 122 of the needle 120 (shown by the arrow CC inFIG. 4 ). - Because the
dermal filler 118 is conveyed from thedistal end portion 122 of theneedle 120 non-manually, the user is not burdened with producing a force in the distal direction (to inject the dermal filler 118) while simultaneously moving thedistal end portion 122 of theneedle 120 in the proximal direction. In this manner, the operation of producing a force to inject thedermal filler 118 is independent from the operation of moving thedistal end portion 122 of theneedle 120. Similarly stated, the operation of producing a force to inject thedermal filler 118 is decoupled from (i.e., is separate and distinct from) the operation of moving thedistal end portion 122 of theneedle 120. This arrangement can result in a repeatable, continuous and/or controlled movement of thedistal end portion 122 of theneedle 120 and/or injection of thedermal filler 118. In contrast, some known medical injectors require the user to use the same hand to produce a force in a distal direction along a longitudinal axis of the medical injector to inject a dermal filler and move the needle along the longitudinal axis, for example, in an opposite (i.e., proximal) direction. In such instances, the injection of the dermal filler can be irregular, uncontrolled and/or discontinuous. Moreover, the disadvantage of such manual injection procedures can be exacerbated when injecting high viscosity dermal fillers, because, as described herein, the force to inject such dermal fillers can be in excess of approximately 4.5 N (10 lbf). For example, when injecting high viscosity dermal fillers using known medical injectors, it can be difficult for the user to maintain the force necessary to inject the dermal filler at the desired flow rate throughout the injection event. Thus, when injecting high viscosity dermal fillers using known medical injectors, the resulting bead of dermal filler can have undesirable spatial variability in its size and/or volume. - Although the
distal end portion 122 of theneedle 120 is shown and described above as being moved in the proximal direction when theenergy source 150 is being actuated, in other embodiments, thedistal end portion 122 can be moved in any manner. For example, in some embodiments thedistal end portion 122 of theneedle 120 can be moved in a distal direction (i.e., in substantially the same direction as the flow of thedermal filler 118 from thedistal end portion 122 of the needle 120). In other embodiments, thedistal end portion 122 of theneedle 120 can be moved in a direction not parallel to a longitudinal axis of theneedle 120. In yet other embodiments, thedistal end portion 122 of theneedle 120 can be rotated when theenergy source 150 is being actuated. For example, in some embodiments, the user can “fan” thedistal end portion 122 of the needle 120 (i.e., move thedistal end portion 122 in a direction not parallel to a longitudinal axis of the needle 120) within the skin SK when the energy source is being actuated. Moreover, thedistal end portion 122 of theneedle 120 can be moved any suitable distance when theenergy source 150 is being actuated. In some embodiments, for example, thedistal end portion 122 of theneedle 120 can be moved a distance of at least 4 millimeters during actuation of theenergy source 150. - Returning to the flow chart shown in
FIG. 1 , in some embodiments, the method can optionally include regulating a flow rate of the dermal filler through the distal end portion of the needle when the energy source is being actuated, at 18. In this manner, the user can adjust the amount the dermal filler being injected within and/or beneath the skin to provide the desired cosmetic and/or therapeutic results. In some embodiments, for example, the flow rate of the dermal filler can be regulated to maintain a substantially constant flow rate of the dermal filler through the distal end portion of the needle when the distal end portion of the needle is moved within and/or beneath the skin. Said another way, in some embodiments, the flow rate of the dermal filler can be regulated to produce a substantially uniform bead of dermal filler within the skin. In some embodiments, for example, the flow rate of the dermal filler can be regulated when the needle is moved within the skin to produce a substantially uniform bead of dermal filler having a volume of approximately 1 to 2 cubic centimeters and a length of between approximately 4 millimeters and 13 millimeters. In other embodiments, the flow rate of the dermal filler can be regulated when the needle is moved within the skin to produce a substantially uniform bead of dermal filler having a volume of less than 1 cubic centimeter and a length of between approximately 4 millimeters and 13 millimeters. For example, in some embodiments, the flow rate of the dermal filler can be regulated when the needle is moved within the skin to produce a substantially uniform bead of dermal filler having a volume of approximately 0.1 to 0.2 cubic centimeter and a length of between approximately 4 millimeters and 13 millimeters. In yet other embodiments, the flow rate of the dermal filler can be regulated when the needle is moved within the skin to produce a substantially uniform bead of dermal filler having a volume of greater than 2 cubic centimeter (e.g., a volume of 3, 4, 5, or 10 cubic centimeters) and a length of up to 150 millimeters. Such a bead can be used, for example, to increase the skin volume in the areas of the nasal labial fold, the jowls and/or the neck region, and can smooth the appearance of wrinkles in those areas. - The flow rate of the dermal filler can be regulated to produce any suitable flow rate. For example, in some embodiments, the flow rate of the dermal filler can be regulated to a substantially constant flow rate of at least approximately 0.02 cubic centimeters per minute. In other embodiments, the flow rate of the dermal filler can be regulated to a substantially constant flow rate of between approximately 0.02 cubic centimeters per minute and 0.5 cubic centimeters per minute. In yet other embodiments, the flow rate of the dermal filler can be regulated to a substantially constant flow rate of as much as 3 cubic centimeters per minute. In still other embodiments, the flow rate of the dermal filler can be regulated to a substantially constant flow rate greater than 3 cubic centimeters per minute.
- Although the flow rate of the dermal filler through the distal end portion of the needle is described above as being regulated to a substantially constant value when the needle is moved within the body, in some embodiments, the flow rate of the dermal filler can be selectively varied during the injection process. In this manner, the user can produce a bead and/or set of beads of dermal filler within the skin having spatially varied volume. Moreover, referring to the flow chart in
FIG. 1 , in some embodiments, themethod 10 can include optionally regulating a flow rate of the dermal filler through the distal end portion of the needle such that the flow rate is substantially zero at a first time after the needle has been moved and still remains in the skin, at 20. Said another way, in some embodiments, themethod 10 can include optionally stopping the flow of the dermal filler through the distal end portion of the needle after the needle has been moved within the skin. The distal end portion of the needle can then be moved while the flow rate of the dermal filler through the distal end portion of the needle is zero, at 22. The flow rate of the dermal filler through the distal end portion of the needle can then be regulated such that the flow rate is increased greater than zero, at 24. In this manner, the user can produce a discontinuous bead and/or set of beads of dermal filler within the skin, as shown inFIG. 5 . In some embodiments, for example, the flow rate of the dermal filler through the distal end portion of the needle can be regulated such that at least one discrete bead from the set of beads has a volume of approximately 0.1 cubic centimeters or less. In other embodiments, the flow rate of the dermal filler through the distal end portion of the needle can be regulated such that at least one discrete bead from the set of beads has a volume of less than approximately 0.01 cubic centimeters or less. In some embodiments, the flow rate of the dermal filler through the distal end portion of the needle can be regulated to produce such a set of discontinuous beads in areas of the skin surrounding the eye. - As described in more detail herein, the flow rate of the dermal filler through the distal end portion of the needle can be regulated in any suitable manner. For example, referring to
FIGS. 2-4 , in some embodiments, the flow rate of thedermal filler 118 through thedistal end portion 122 of theneedle 120 can be regulated by selectively controlling the energy from theenergy source 150 to themedical injector 100. Said another way, in some embodiments, the flow rate of thedermal filler 118 through thedistal end portion 122 of theneedle 120 can be regulated by mechanisms outside of the flow path of thedermal filler 118. Moreover, in some embodiments, the flow rate of thedermal filler 118 through thedistal end portion 122 of theneedle 120 can be regulated via theactuator 153. For example, in some embodiments, the user can repeatedly and/or controllably actuate theenergy source 150 using theactuator 153. Said another way, in some embodiments, the user can repeatedly toggle theactuator 153 to selectively couple theenergy source 150 to and decouple theenergy source 150 from themedicament injector 100. In this manner, for example, the flow rate of the dermal filler can be regulated to produce a discontinuous bead and/or set of beads of dermal filler within the skin, as described above. - In other embodiments, the flow rate of the
dermal filler 118 through thedistal end portion 122 of theneedle 120 can be regulated by selectively restricting the flow path of thedermal filler 118 within themedical injector 100 and/or theneedle 120. For example, in some embodiments, the flow rate of thedermal filler 118 through thedistal end portion 122 of theneedle 120 can be regulated by a valve within the medicament flow path. -
FIGS. 6 and 7 are schematic illustrations of amedical device 200, according to an embodiment configured inject amedicament 218. Themedical device 200 includes amedicament container 210, aneedle 220, anenergy source 250 and aregulator 260. Themedicament container 210 includes apiston 214 movably disposed therein, such that themedicament container 210 is divided into afirst portion 215 and asecond portion 217. In some embodiments, for example, thepiston 214 can be disposed within themedicament container 210 such that thefirst portion 215 of themedicament container 210 is fluidically isolated from thesecond portion 217 of themedicament container 217. - The
first portion 215 of themedicament container 210 is configured to contain amedicament 218 having a high viscosity (i.e., a medicament having a viscosity of at least 100 Poise). Themedicament 218 can be any medicament suitable for being injected into a body. For example, in some embodiments, themedicament 218 can be a high viscosity dermal filler (e.g., a liquid dermal filler, a paste-like dermal filler, a dermal filler including both a liquid component and a solid component, or the like). In some embodiments, themedicament 218 can have a viscosity of at least 1000 Poise (100 N-sec/m2). In other embodiments, themedicament 218 can have a viscosity of at least 10,000 Poise. In yet other embodiments, themedicament 218 can have a viscosity of at least 100,000 Poise. - In some embodiments, the
medicament 218 can be a fluid that is characterized by a substantially linear shear stress as a function of the rate of shear strain applied thereto. Said another way, in some embodiments, themedicament 218 can be a Newtonian fluid having a viscosity that varies substantially only as a function of its temperature and pressure. In other embodiments, themedicament 218 can be a fluid that is characterized by a non-linear shear stress as a function of the rate of shear strain applied thereto. Said another way, in some embodiments, themedicament 218 can be a non-Newtonian fluid having a viscosity that varies according other factors, such as, for example, the magnitude of and/or rate of increase of a force applied to themedicament 218. - The
needle 220 is coupled to themedicament container 210 such that theneedle 220 is in fluid communication with thefirst portion 215 of themedicament container 210. Theneedle 220 can be coupled to themedicament container 210 by any suitable mechanism. For example, in some embodiments, theneedle 220 can be coupled to themedicament container 210 by a Luer fitting that provides a substantially fluid-tight seal (i.e., a seal that that substantially prevents a liquid and/or a gas from passing therethrough) between theneedle 220 and themedicament container 210. In some embodiments, the fluid-tight seal can be a hermetic seal (i.e., a seal that substantially prevents a gas from passing therethrough). - The
needle 220 can have any suitable bore size and length. For example, in some embodiments, the needle can have a small bore to reduce patient discomfort during a procedure. For example, in some embodiments, theneedle 220 can define a lumen having a nominal inner diameter of less than or equal to approximately 0.191 millimeters (i.e., a 27 gauge needle). In other embodiments, theneedle 220 can define a lumen having a nominal inner diameter of less than or equal to approximately 0.140 millimeters (i.e., a 30 gauge needle). In some embodiments, for example, theneedle 220 can define a lumen having a nominal inner diameter of approximately 0.114 millimeters (i.e., a 31 gauge needle). In some embodiments, for example, theneedle 220 can define a lumen having a nominal inner diameter of approximately 0.089 millimeters (i.e., a 32 gauge needle). In some embodiments, theneedle 220 can have a length of at least 17 millimeters. - When the
piston 214 moves within themedicament container 210, as shown by the arrow DD inFIG. 7 , themedicament 218 is conveyed from thefirst portion 215 of themedicament container 210. Said another way, a user can inject themedicament 218 into a body by actuating themedical device 200 to cause thepiston 214 to move distally within themedicament container 210. As shown inFIGS. 6 and 7 , theenergy source 250 is operatively coupled to thepiston 214 such that thepiston 214 can be moved non-manually. Theenergy source 250 can be any suitable form of energy configured produce kinetic energy to move thepiston 214 within themedicament container 210. The amount of kinetic energy required to move thepiston 214 within themedicament container 210 is dependent on, among other things, the viscosity of themedicament 218, the desired flow rate of themedicament 218 through thedistal end portion 222 of theneedle 220, the length of theneedle 220 and/or the size of the lumen defined by theneedle 220. In some embodiments, theenergy source 250 can produce kinetic energy sufficient to move thepiston 214 such that amedicament 218 having a viscosity of at least 1000 Poise can be injected through thedistal end portion 222 of the needle at a flow rate of at least 0.02 cubic centimeters per minute. In other embodiments, theenergy source 250 can produce kinetic energy sufficient to move thepiston 214 such that amedicament 218 having a viscosity of at least 1000 Poise can be injected through thedistal end portion 222 of the needle at a flow rate of at least 0.5 cubic centimeters per minute. In yet other embodiments, theenergy source 250 can produce kinetic energy sufficient to move thepiston 214 such that amedicament 218 having a viscosity of at least 10,000 Poise can be injected through thedistal end portion 222 of theneedle 220 at a flow rate of at least 0.5 cubic centimeters per minute. In still other embodiments, theenergy source 250 can produce kinetic energy sufficient to move thepiston 214 such that amedicament 218 having a viscosity of at least 10,000 Poise can be injected through thedistal end portion 222 of theneedle 220 at a flow rate of at least 3 cubic centimeters per minute. In still other embodiments, theenergy source 250 can produce kinetic energy sufficient to move thepiston 214 such that amedicament 218 having a viscosity of at least 10,000 Poise can be injected through thedistal end portion 222 of theneedle 220 at a flow rate of between 3 and 5 cubic centimeters per minute. - Additionally, the pressure of the
medicament 218 within themedicament container 210 during an injection event is related to the kinetic energy applied to thepiston 214, and is therefore also dependent on, among other things, the viscosity of themedicament 218, the desired flow rate of themedicament 218 through thedistal end portion 222 of theneedle 220, the length of theneedle 220 and/or the size of the lumen defined by theneedle 220. In certain circumstances, the pressure of themedicament 218 within themedicament container 210 can be modeled by the Hagen-Poiseuille law, as indicated below: -
P=(8*μ*L*Q)/(π*R 4) (1) - where P is the pressure of the
medicament 218 within the medicament container, μ is the viscosity of themedicament 218, L is the length of theneedle 220, Q is the flow rate of themedicament 218 through thedistal end portion 222 of theneedle 220, and R is the radius of the lumen defined by theneedle 220. Because the pressure required to inject a high viscosity fluid through a small-bore needle is proportional to the inverse of the radius of the lumen of the needle to the fourth power, the pressure of themedicament 218 within themedicament container 210 necessary to achieve the desired flow rate can, at times, be relatively high. In some embodiments, theenergy source 250 can be configured to move thepiston 214 within themedicament container 210 such that a pressure of themedicament 218 within themedicament container 210 is greater than 345 kilopascals (50 p.s.i.). In other embodiments, theenergy source 250 can be configured to move thepiston 214 within themedicament container 210 such that a pressure of themedicament 218 within themedicament container 210 is greater than 690 kilopascals (100 p.s.i.). In still other embodiments, theenergy source 250 can be configured to move thepiston 214 within themedicament container 210 such that a pressure of themedicament 218 within themedicament container 210 is greater than 1035 kilopascals (150 p.s.i.). In still other embodiments, theenergy source 250 can be configured to move thepiston 214 within themedicament container 210 such that a pressure of themedicament 218 within themedicament container 210 is greater than 34.5 Megapascals (5000 p.s.i.). - The
regulator 260 is configured to regulate the flow rate of themedicament 218 through thedistal end portion 222 of theneedle 220. In this manner, the user can adjust the flow rate of themedicament 218 through thedistal end portion 222 of theneedle 220. In some embodiments, for example, theregulator 260 can substantially stop the flow of themedicament 218 through thedistal end portion 222 of theneedle 220. In this manner, as described above, the user can discontinuously inject themedicament 218 within the body. - The
regulator 260 can be any suitable mechanism for regulating the flow rate of themedicament 218 through thedistal end portion 222 of theneedle 220. As described above, in some embodiments, theregulator 260 can control the transmission of energy from theenergy source 250 to thepiston 214. In other embodiments, theregulator 260 can selectively restrict the flow path of themedicament 218 within thefirst portion 215 of themedicament container 210 and/or theneedle 220. -
FIGS. 8-10 show asystem 300 that employs a pressurized fluid to inject a dermal filler according to an embodiment. Thesystem 300 includes amedicament container 310, a needle (not shown inFIG. 8 ), a source of pressurized fluid 351 (seeFIGS. 9 and 10 ), a regulator 360 (seeFIGS. 9 and 10 ), and anadapter 330 configured to couple themedicament container 310 to the source ofpressurized fluid 351. Themedicament container 310 is a substantially rigid container having aproximal end portion 311 and adistal end portion 312. Themedicament container 310 includes apiston 314 movably disposed therein such that themedicament container 310 is divided into afirst portion 315 and asecond portion 317. Thefirst portion 315 of themedicament container 310 is configured to contain a dermal filler 318 having a high viscosity. The medicament 318 can be any medicament suitable for being injected into a body, as described herein. - A
coupler 325 is disposed at thedistal end portion 312 of themedicament container 310. Thecoupler 325 is configured to removably couple the needle (not shown inFIG. 8 ) to thedistal end portion 312 of themedicament container 310 such that the needle is in fluid communication with thefirst portion 315 of themedicament container 310. Thecoupler 325 can include any suitable coupling mechanism configured to produce a substantially fluid-tight coupling between the needle and themedicament container 310. For example, in some embodiments, thecoupler 325 can be a Luer lock fitting that threadedly engages a hub of the needle and maintains the hub in position about a protrusion (not shown inFIG. 8 ) at thedistal end portion 312 of themedicament container 310. In such an arrangement, the protrusion and the needle hub can have mating tapered surfaces such that a substantially fluid-tight interface is produced when the needle hub is coupled to themedicament container 310 by thecoupler 325. - The
adapter 330, which is configured to couple themedicament container 310 to the source ofpressurized fluid 351, includes atube 342 and acoupler 343. Thetube 342 includes aproximal end portion 347 and adistal end portion 348. Thedistal end portion 348 of thetube 342 is disposed about abarbed fitting 313 of themedicament container 310 to couple themedicament container 310 to theadapter 330. Thedistal end portion 348 of thetube 342 can be secured about thebarbed fitting 313, for example, by the elastic properties of the tube 342 (i.e., an interference fit between thetube 342 and the barbed fitting 313), an external clamp (not shown), an adhesive, and/or the like. Thecoupler 343 is coupled to theproximal end portion 347 of thetube 342, and is configured to couple thetube 342 to the source ofpressurized fluid 351, as described in more detail below. - As shown in
FIGS. 9 and 10 , the source ofpressurized fluid 351 and theregulator 360 are contained within thehousing 354. In this manner, the flow rate and/or the pressure of the pressurized fluid delivered from the source ofpressurized fluid 351 to themedicament container 310 can be regulated and/or actuated by the integrated assembly within thehousing 354. The source ofpressurized fluid 351 can include any suitable fluid (e.g., a gas or a liquid) configured to produce a pressure when conveyed to thesecond portion 317 of themedicament container 310, as described in more detail below. In some embodiments, for example, the source ofpressurized fluid 351 can be a compressed CO2 cartridge configured to be threadedly coupled to thehousing 354. In other embodiments, the source ofpressurized fluid 351 can include a reservoir, an accumulator and/or an adapter configured to receive a pressurized gas from an external source (i.e., a facility gas supply system). - The
housing 354 includes anactuator 353, acoupler fitting 355 and aregulator knob 361. Thecoupler fitting 355 is configured to receive thecoupler 343 of theadapter 330 such that theproximal end portion 347 of thetube 342 can be removably coupled to thehousing 354. In this manner, themedicament container 310 can be coupled to the source ofpressurized fluid 351. Said another way, in this manner, thepiston 314 can be operatively coupled to the source ofpressurized fluid 351. Said yet another way, in this manner, thesecond portion 317 of themedicament container 310 can be placed in a fluidic circuit with the source ofpressurized fluid 351 such that thesecond portion 317 of themedicament container 310 can be selectively placed in fluid communication with the source ofpressurized fluid 351. - The
actuator 353, which can be, for example, a push button actuator, is configured to selectively place thesecond portion 317 of themedicament container 310 in fluid communication with the source ofpressurized fluid 351. Similarly stated, theactuator 353 can selectively limit the flow rate and/or the pressure of the pressurized fluid delivered from the source ofpressurized fluid 351 to thesecond portion 317 of themedicament container 310. In this manner, the user can actuate theactuator 353 to initiate the non-manual injection of the dermal filler 318 from themedicament container 310 through the needle (not shown inFIG. 8 ). As described above, because the dermal filler 318 is conveyed from themedicament container 310 non-manually, the user is not burdened with producing the energy and/or force necessary to cause the dermal filler 318 to be conveyed at the desired flow rate. This arrangement can result in a repeatable, continuous and/or controlled injection of the dermal filler 318. - Although the
actuator 353 is shown as being actuated by a push button disposed on thehousing 354, in other embodiments, theactuator 353 can be actuated via a foot switch (not shown inFIGS. 9 and 10 ) coupled to thehousing 354. In such embodiments, the user can initiate the injection of the dermal filler 318 in a “hands free” manner, thereby allowing the user to use their hands to control the placement and/or the movement of the needle within the body. In such embodiments, the foot switch can be any suitable switch configured to cause theactuator 353 to selectively place thesecond portion 317 of themedicament container 310 in fluid communication with the source ofpressurized fluid 351. The foot switch can be, for example, an electronic switch, a pneumatic switch or the like. In some embodiments, for example, the foot switch can be wirelessly coupled to theactuator 353. - The
regulator knob 361 can be used to adjust theregulator 360 to selectively regulate the flow rate and/or the pressure of the pressurized fluid delivered from the source ofpressurized fluid 351 to thesecond portion 317 of themedicament container 310 when theactuator 353 is actuated. In this manner, the flow rate of the dermal filler 318 from themedicament container 310 can be regulated. This arrangement allows the flow rate of the dermal filler 318 to be regulated without affecting the flow path of the dermal filler 318 and/or without any portion of theregulator 360 contacting the dermal filler 318. - The
regulator 360 can be any suitable mechanism configured to regulate the flow rate and/or the pressure of the pressurized fluid from the source ofpressurized fluid 351. For example, in some embodiments, theregulator 360 include components from an EFD® dispensing system, such as, for example, the EFD® 2400 pneumatic dispenser or the EFD® 2800 hydraulic controller manufactured by EFD, Inc. (a Nordson Company). - In some embodiments, the
distal end portion 348 of thetube 342 is removably coupled to themedicament container 310. In this manner, a kit according to an embodiment can include theadapter 330 and one ormore medicament containers 310 pre-filled with the dermal filler 318. For example, in some embodiments, a kit can includemultiple medicament containers 310 pre-filled with different volumes of the dermal filler 318. In this manner, the user can select from among thepre-filled medicament containers 310 based on the amount of dermal filler 318 to be injected (e.g., the amount of dermal filler necessary for the desired cosmetic and/or therapeutic result). For example, in some embodiments, a kit can includepre-filled medicament containers 310 containing approximately 1 cubic centimeter, 2 cubic centimeters, 3 cubic centimeters, 5 cubic centimeters and/or 10 cubic centimeters of dermal filler 318. In other embodiments, a kit can includepre-filled medicament containers 310 containing greater than 10 cubic centimeters of dermal filler 318. - Such pre-filled medicament containers can accommodate increased volume of the dermal filler 318 by having an increased length and/or an increased inner diameter. Because the dermal filler 318 is injected non-manually, as described above, the length and/or the inner diameter of the
medicament container 310 can be varied without regard to the physical limitations associated with actuating the medicament container manually. More particularly, because the dermal filler 318 is injected non-manually, the length and/or the inner diameter of themedicament container 310 can be varied independently from the distance through which an average user can manually depress a plunger and/or the force that an average user can apply when manually depressing a plunger. - In contrast, some known medical injectors are limited in the volume of dermal filler that can be contained therein because of the physical constraints imposed by manually actuating the medical injector. More particularly, some known medical injectors are configured contain a maximum of approximately 1 cubic centimeter of dermal filler. In such known manually-actuated injectors, the medicament pressure during injection is inversely proportional to the square of the inner diameter. Thus, increasing the size of the inner diameter to allow a greater volume of dermal filler to be contained within the medical injector can result in an increase in the force required to generate the desired medicament pressure. Accordingly, because the force that can be applied manually by a user is limited, increasing the size of the inner diameter is often not desirable. Similarly, the length of travel of the piston within the medicament container (i.e., the stroke of the injector) can be increased to allow a greater volume of dermal filler to be contained within the medical injector. However, the distance through which the piston can be moved is also limited based on the size of the user's hand.
- Although the
adapter 330 is shown and described above as being coupled to themedicament container 310 via thebarbed fitting 313, in other embodiments, an adapter can be coupled to a medicament container having a flange. In this manner, the adapter can be configured to receive a flanged syringe. One such embodiment is shown inFIG. 11 , which shows a portion of asystem 400 that employs a pressurized fluid to inject a dermal filler according to an embodiment. Thesystem 400 includes amedicament container 410, a needle (not shown inFIG. 11 ), a source of pressurized fluid (not shown inFIG. 11 ), and anadapter 430 configured to couple themedicament container 410 to the source of pressurized fluid. The source of pressurized fluid can be similar to the source ofpressurized fluid 351 shown and described above. Additionally, thesystem 400 can include a regulator similar toregulator 360 shown and described above, and an actuator similar to theactuator 353 shown and described above. Accordingly, only themedicament container 410 and theadapter 430 are discussed in detail below. - The
medicament container 410, which can be, for example, a commercially-available syringe, has aproximal end portion 411 and adistal end portion 412. Themedicament container 410 includes apiston 414 movably disposed therein such that themedicament container 410 is divided into afirst portion 415 and asecond portion 417. Thefirst portion 415 of themedicament container 410 is configured to contain a dermal filler 418 having a high viscosity. The medicament 418 can be any medicament suitable for being injected into a body, as described herein. Acoupler 425 is disposed at thedistal end portion 412 of themedicament container 410. As described above, thecoupler 425 is configured to removably couple the needle (not shown inFIG. 11 ) to thedistal end portion 412 of themedicament container 410. - The
adapter 430, which is configured to couple themedicament container 410 to the source of pressurized fluid, includes ahand piece 449, atube 442 and acoupler 443. Thehand piece 449 includes aproximal end portion 431, adistal end portion 432, and an outer surface that can be contoured to assist the user in gripping and/or manipulating thehand piece 449. Thedistal end portion 432 of thehand piece 449 includes acoupler 433 configured to removably couple thehand piece 449 to themedicament container 410. More particularly, thecoupler 433 is configured to couple thehand piece 449 to a standard, commercially-available syringe. In this manner, theadapter 430 can be used on a variety ofdifferent medicament containers 410. - The
coupler 433 includes aprotrusion 434, a sealingmember 435, and twocoupling members 436. Theprotrusion 434 is configured to be disposed within thesecond portion 417 of themedicament container 410 when thecoupler 433 is coupled to themedicament container 410. The sealingmember 435 is disposed about theprotrusion 434 and forms a substantially fluid-tight seal between theprotrusion 434 and the inner surface of themedicament container 410 when thecoupler 433 is coupled to themedicament container 410. In this manner, the pressurized fluid conveyed from the source of pressurized fluid to thesecond portion 417 of themedicament container 410 is maintained within thesecond portion 417 of the medicament container 410 (i.e., the pressurized fluid does not leak out of thesecond portion 417 of the medicament container 410). The sealingmember 435 can be, for example, an o-ring, and can be constructed from any suitable material that is compatible with the medicament 418 and/or the pressurized fluid from the source of pressurized fluid. - The
coupling members 436 are disposed approximately equidistance circumferentially about thecoupler 433. Said another way, thecoupling members 436 are disposed approximately 180 degrees apart. In this manner thecoupling members 436 engage theflange 413 of themedicament container 410 at two distinct circumferential locations when thecoupler 433 is coupled to themedicament container 410. As shown inFIG. 11 , eachcoupling member 436 includes aprotrusion 437 that defines a channel within which theflange 413 of themedicament container 410 is received when thecoupler 433 is coupled to themedicament container 410. More particularly, eachcoupling members 436 is configured to bend outwardly, as shown by the arrow EE, when pressed against theflange 413 to allow theflange 413 be disposed within the channel. When theflange 413 is disposed within the channel, the coupling members move back to their respective relaxed positions such that theflange 413 and thecoupling members 436 cooperatively limit the axial movement of themedicament container 410 relative to thehand piece 449. - The
tube 442 includes aproximal end portion 447 and adistal end portion 448. Thedistal end portion 448 of thetube 442 is coupled to the barbed fitting at theproximal end portion 431 of thehand piece 449. Thedistal end portion 448 of thetube 442 can be secured about the barbed fitting, for example, by the elastic properties of the tube 442 (i.e., an interference fit between thetube 442 and the barbed fitting), an external clamp (not shown), an adhesive, and/or the like. Thecoupler 443 is coupled to theproximal end portion 447 of thetube 442, and is configured to couple thetube 442 to the source of pressurized fluid, as described above. - Although the
adapter 430 is shown as being configured to convey a pressurized fluid into thesecond portion 417 of themedicament container 410, in other embodiments, an adapter and/or a hand piece can be configured to indirectly couple a medicament container and/or a piston to a source of pressurized fluid. For example, in some embodiments, an adapter and/or a hand piece can be configured to convert and/or amplify the pressure produced by the source of pressurized fluid to move a piston with sufficient force to generate the desired medicament flow rates and/or medicament pressure. One such embodiment is shown inFIG. 12 , which shows a portion of a system 500 that employs a pressurized fluid to inject a dermal filler according to an embodiment. The system 500 includes amedicament container 510, aneedle 520, a source of pressurized fluid (not shown inFIG. 12 ), and anadapter 530 configured to couple themedicament container 510 to the source of pressurized fluid. The source of pressurized fluid can be similar to the source ofpressurized fluid 351 shown and described above. Additionally, the system 500 can include a regulator similar toregulator 360 shown and described above, and an actuator similar to theactuator 353 shown and described above. Accordingly, only theadapter 530 and themedicament container 510 are discussed below. - The
medicament container 510 has aproximal end portion 511 and adistal end portion 512. Thedistal end portion 512 is coupled to theneedle 520, as discussed above. Theproximal end portion 511 is coupled to theadapter 530, as discussed below. Themedicament container 510 includes afirst piston 514 movably disposed therein. Thefirst piston 514 has a diameter d1. - The
adapter 530 includes ahand piece 549, atube 542 and acoupler 543. Thetube 542 includes aproximal end portion 547 and adistal end portion 548. Thedistal end portion 548 of thetube 542 is coupled to theproximal end portion 531 of thehand piece 549. Thecoupler 543 is coupled to theproximal end portion 547 of thetube 542, and is configured to couple thetube 542 to the source of pressurized fluid, as described above. In this manner, a pressurized fluid can be conveyed from the source of pressurized fluid into thehand piece 549, as described below. - The
hand piece 549 includes aproximal end portion 531 and adistal end portion 532. Thedistal end portion 532 of thehand piece 549 includes acoupler 533 configured to removably couple thehand piece 549 to themedicament container 510. As described above, thecoupler 533 includes twocoupling members 536 that are disposed approximately equidistance circumferentially about thecoupler 533. Said another way, thecoupling members 536 are disposed approximately 180 degrees apart. In this manner thecoupling members 536 engage theflange 513 of themedicament container 510 at two distinct circumferential locations when thecoupler 533 is coupled to themedicament container 510. - The
hand piece 549 defines alumen 544, within which asecond piston 546, having a diameter d2, and apush rod 545 are movably disposed. When thehand piece 549 is coupled to themedicament container 510 by thecoupler 533, thesecond piston 546 is coupled to thefirst piston 514 by thepush rod 545. Accordingly, when thehand piece 549 is coupled to themedicament container 510 by thecoupler 533, a force acting on thesecond piston 546 is transferred directly to thefirst piston 514. In this manner, when a pressurized fluid from the source of pressurized fluid is conveyed into thelumen 544, the force exerted by the pressurized fluid on thesecond piston 546 is transferred to thefirst piston 514. - The corresponding pressure of the dermal filler in the medicament container 510 (P1) and the pressure of the pressurized fluid in the
lumen 544 of the hand piece 549 (P2) are defined by equations (2) and (3) below: -
P1=F/A1 (2) -
P2=F/A2 (3), - where F is the force exerted by the pressurized fluid on the
second piston 546, and A1 and A2 are the surface area of thefirst piston 514 and thesecond piston 546, respectively. Because the force F acting on thefirst piston 514 is the same as the force F acting on thesecond piston 546 under steady-state conditions, equations (2) and (3) can be rearranged to define the relationship between the pressure P2 of the pressurized fluid and the pressure P1 of the dermal filler: -
P1=(A2/A1)*P2 (4). - As illustrated by equation (4), the delivery pressure P1 of the dermal filler in the medicament container can be controlled by controlling the pressure P2 of the pressurized fluid in the
hand piece 549 and/or by adjusting the area ratio (also referred to as the amplification factor) of thesecond piston 546 and thefirst piston 514. In this manner, thehand piece 549 can amplify the pressure of the pressurized fluid. - The
hand piece 549 can be configured to produce any desired amount of pressure amplification. For example, in some embodiments, thefirst piston 514 can have a diameter d1 (i.e., the inner diameter of the medicament container 510) of approximately 5 mm (0.20 inches), and thesecond piston 546 can have a diameter d2 of approximately 22 mm (0.88 inches). In such embodiments, the amplification factor is approximately 19.3. Accordingly, a pressure within thehand piece 549 of approximately 890 kPa (130 p.s.i.) will result in a pressure within the medicament container of approximately 17.2 MPa (2500 p.s.i.). - In other embodiments, it is desirable for the
first piston 514 to have a diameter greater than 5 mm. For example, in some embodiments, themedicament container 510 is configured to contain approximately 2 cubic centimeters of dermal filler, and therefore has an inner diameter of approximately 7 mm (0.28 inches). Thesecond piston 546 can have a diameter d2 of approximately 22 mm (0.88 inches), resulting in an amplification factor of approximately 9.9. Accordingly, a pressure within thehand piece 549 of approximately 690 kPa (100 p.s.i.) will result in a pressure within the medicament container of approximately 6.9 MPa (1000 p.s.i.). - In some embodiments, it is desirable for the
second piston 546 to have a diameter less than 22 mm, for example, to provide improved maneuverability during use. For example, in some embodiments, themedicament container 510 is configured to contain approximately 2 cubic centimeters of dermal filler, and has an inner diameter of approximately 7 mm (0.28 inches). Thesecond piston 546 can have a diameter d2 of approximately 15.7 mm (0.62 inches), resulting in an amplification factor of approximately 5. Accordingly, a pressure within thehand piece 549 of approximately 690 kPa (100 p.s.i.) will result in a pressure within the medicament container of approximately 3.5 MPa (500 p.s.i.). - Although the
adapter 530 is shown and described above as being coupled to themedicament container 510 by twocoupling members 536 configured to engage theflange 513 of themedicament container 510, in other embodiments, an adapter can be coupled to a medicament container in any suitable manner. For example, in some embodiments, an adapter can be coupled to a medicament container by three, four, or more coupling members. In this manner, the medicament container can be securely fastened to the adapter to withstand the high pressures (and therefore the resulting forces) that can be applied during use. In other embodiments, an adapter can be coupled to a medicament container by a nut configured to engage a flange of the medicament container substantially around the entire circumference of the flange. For example,FIG. 13 shows a portion of asystem 600 that employs a pressurized fluid to inject a dermal filler according to an embodiment. Thesystem 600 includes amedicament container 610, aneedle 620, a source of pressurized fluid (not shown inFIG. 13 ), and anadapter 630 configured to couple themedicament container 610 to the source of pressurized fluid. Thesystem 600 is similar in many respects to the system 500 described above, and is therefore not described in detail below. Thesystem 600 differs, however, in that theadapter 630 is coupled to themedicament container 610 by acoupling nut 639. - The
coupling nut 639 is disposed about theproximal end portion 611 of themedicament container 610 such that a shoulder (not shown) of thecoupling nut 639 engages the flange (not shown) of themedicament container 610. Thecoupling nut 639 is configured to be threadedly coupled to thedistal end portion 632 of thehand piece 649. In this manner, when thecoupling nut 639 is tightened on to thehand piece 649, the shoulder of thecoupling nut 639 exerts a coupling force around the circumference of the flange of themedicament container 610. - Although the
regulator 360 is shown and described above as controlling flow rate of dermal filler by regulating the flow rate and/or the pressure of the pressurized fluid delivered from the source ofpressurized fluid 351 to themedicament container 310, in other embodiments, a regulator can regulate the flow rate of dermal filler by obstructing and/or modifying a flow path of the dermal filler. Similarly stated, although theregulator 360 is shown and described above as being disposed outside of the flow path of the dermal filler, in other embodiments, a regulator can have at least a portion disposed within the flow path of the dermal filler. For example,FIGS. 14-17 show asystem 600 that includes a self-contained source of pressurized gas to inject a dermal filler according to an embodiment. - The
system 700 includes amedicament container 710, aneedle 720, a source ofpressurized fluid 750, and anadapter 730 configured to couple themedicament container 710 to the source of pressurized fluid. Themedicament container 710 has aproximal end portion 711 and adistal end portion 712. Themedicament container 710 includes afirst piston 714 movably disposed therein. Thefirst piston 714 has a diameter d1. Themedicament container 710 is configured to contain a dermal filler having a high viscosity. Theregulator 760 is disposed at thedistal end portion 712 of themedicament container 710. As described in more detail below, acoupler 725 is attached to the regulator and is configured to removably couple theneedle 720 to the regulator, and thus to thedistal end portion 712 of themedicament container 710. Thecoupler 725 can be any suitable coupler, as described above. Thedistal end portion 712 of themedicament container 710 includes aflange 713 that can be coupled to theadapter 730, as described below. - The
adapter 730 includes aproximal end portion 731 and adistal end portion 732. Thedistal end portion 732 of theadapter 730 includes acoupler 733 configured to removably couple theadapter 730 to themedicament container 710. As described above, thecoupler 733 includes twocoupling members 736 that are disposed approximately equidistance circumferentially about thecoupler 733. Said another way, thecoupling members 736 are disposed approximately 180 degrees apart. In this manner thecoupling members 736 engage theflange 713 of themedicament container 710 at two distinct circumferential locations when thecoupler 733 is coupled to themedicament container 710. - The
adapter 730 defines alumen 744, within which asecond piston 746, having a diameter d2, and apush rod 745 are movably disposed. When theadapter 730 is coupled to themedicament container 710 by thecoupler 733, thesecond piston 746 is coupled to thefirst piston 714 by thepush rod 745. Accordingly, when theadapter 730 is coupled to themedicament container 710 by thecoupler 733, a force acting on thesecond piston 746 is transferred directly to thefirst piston 714. In this manner, when a pressurized fluid from the source ofpressurized fluid 750 is conveyed into thelumen 744, the force exerted by the pressurized fluid on thesecond piston 746 is transferred to thefirst piston 714. As shown inFIG. 14 , the diameter d2 of thesecond piston 746 is greater than the diameter d1 of thefirst piston 714. In this manner, as described above, the pressure within themedicament container 710 can be greater than the pressure supplied by the source ofpressurized fluid 750. Said another way, in this manner, theadapter 730 is configured to amplify the pressure of the pressurized fluid from the source ofpressurized fluid 750. In some embodiments, for example, diameter d1 of thefirst piston 714 can be approximately 7 mm (0.28 inches) and the diameter d2 of thesecond piston 746 can be approximately 12.7 mm (0.5 inches). With such an arrangement, when the pressure provided by the source ofpressurized fluid 750 is approximately 534 kPa (76 p.s.i.), the pressure of the dermal filler within themedicament container 710 is approximately 1.7 MPa (250 p.s.i.). - The outer surface of the
adapter 730 defines anopening 727 in fluid communication with thelumen 744. Theopening 727 is positioned towards adistal end portion 732 of theadapter 730, and is configured to allow fluid within thelumen 744 distally of thesecond piston 746 to evacuate from theadapter 730 when thesecond piston 746 moves distally within theadapter 730. In some embodiments, theopening 727 can include a membrane configured to allow fluids to move through the opening in only one direction. In other embodiments, theopening 727 can be configured to allow fluids to flow freely therethrough in any direction. - The source of
pressurized fluid 750 is movably coupled to theproximal end portion 731 of theadapter 730. More particularly, the source ofpressurized fluid 750 can be actuated by moving the source ofpressurized fluid 750 relative to theadapter 730. In this manner, a valve (not shown inFIG. 14 ) can be opened thereby releasing pressurized fluid from the source ofpressurized fluid 750 into thelumen 744 of theadapter 730. In some embodiments, for example, a release valve (not shown inFIG. 14 ) can be actuated when the source ofpressurized fluid 750 is moved relative to theadapter 730, thereby releasing a pressurized fluid into thelumen 744 of the adapter. The source ofpressurized fluid 750 can be any suitable source of pressurized fluid, including those described in U.S. Provisional Application Ser. No. 61/016,223, entitled “Self-Contained Pressurized Injection Device,” filed Dec. 21, 2007, which is incorporated herein by reference in its entirety. - As shown in
FIGS. 15-17 , theregulator 760 includes aregulator body 761, avalve member 770, avalve actuator 780, and avalve seat 790. Thevalve actuator 780 includes alever 781 and twoelongated members 782. Each of theelongated members 782 includes aprotrusion 783, which can be disposed within the regulator body 761 (see e.g.,FIG. 17 ). In this manner, whenlever 781 of thevalve actuator 780 is moved, thevalve actuator 780 can pivot about theprotrusions 783. - The
regulator body 761 includes aproximal end portion 762 and adistal end portion 763, and defines alumen 764 therethrough. The side wall of theregulator body 761 definesopenings 765 within which a portion of theactuator 780 can be disposed, as described in more detail herein. Thedistal end portion 763 of theregulator body 761 includes astem 766, a portion of which is disposed within thehub 724 of theneedle 720. As described above, thecoupler 725 is attached to thestem 766, and is configured to removably couple theneedle 720 to theregulator 760. Theproximal end portion 762 of theregulator body 761 is disposed about and coupled to thedistal end portion 712 of themedicament container 710. Theproximal end portion 762 of theregulator body 761 can be coupled to thedistal end portion 712 of themedicament container 710 by any suitable means, such as, for example, an adhesive, a crimped fit, an external clamp or the like. - As shown in
FIG. 17 , a mountingring 795 is disposed between theproximal end portion 762 of theregulator body 761 and thedistal end portion 712 of themedicament container 710 to provide a substantially fluid-tight seal between theregulator body 761 and themedicament container 710. Moreover, thevalve seat 790 is coupled to the mountingring 795 such that aseat surface 792 is disposed within themedicament container 710 facing in a proximal direction. In this manner, the mountingring 795 can position thevalve seat 790 relative to theregulator body 761 and/or thevalve member 770. - The
valve member 770 includes aproximal end portion 771 and adistal end portion 772, and defines alumen 777. Thedistal end portion 772 of thevalve member 770 includes ashoulder 779, aseal 774, and defines anactuation groove 775. As shown inFIG. 17 , theseal 774 is configured to engage an inner surface of theregulator body 761 to form a substantially fluid-tight seal between thevalve member 770 and theregulator body 761. Theactuation groove 775 is configured to receive a portion of eachelongated member 782 of thevalve actuator 780. In this manner, as described in more detail herein, movement of theactuator 780 can cause thevalve member 770 to move longitudinally within theregulator body 761. Theproximal end portion 771 of thevalve member 770 includes ahead 778 and definesopenings 776. Theopenings 776 extend through the side wall of thevalve member 770 and are in fluid communication with thelumen 777 of thevalve member 770. - The
valve member 770 is movably disposed within thelumen 764 of thevalve body 761 between a first position (e.g., a closed position, as shown inFIG. 17 ), a second position (e.g., a fully opened position, not shown inFIGS. 14-17 ), and any number of positions therebetween. In this manner, theregulator 760 can regulate the flow rate of dermal filler from themedicament container 710 through theneedle 720. When thevalve member 770 is in the first position, thehead 778 of thevalve member 770 is disposed against theseat surface 792 of thevalve seat 790 to form a substantially fluid-tight seal, as shown inFIG. 17 . Accordingly, when thevalve member 770 is in the first position, the dermal filler cannot flow from themedicament container 710 through theneedle 720. Said another way, when thevalve member 770 is in the first position, the flow rate of the dermal filler from themedicament container 710 is substantially zero. Moreover, because the pressure within themedicament container 710 produces a force on thehead 778 in a distal direction, the pressure within the medicament container tends to maintain thevalve member 770 in the first position. Additionally, as shown inFIG. 17 , when thevalve member 770 is in the first position, theshoulder 779 of thevalve member 770 is disposed against a distal portion of thevalve seat 790. In this manner, thevalve member 770 is maintained in the first position by the force of thevalve seat 790 on theshoulder 779. - To move the
valve member 770 from the first position to the second position, the user can move thelever 781 of thevalve actuator 780 inward, as shown by the arrow FF inFIG. 17 . As described above, the inward movement of thelever 781 causes thevalve actuator 780 to pivot about theprotrusions 783. In this manner, theelongated members 782 of thevalve actuator 780 move proximally. A portion of each of theelongate members 782 is disposed within theactuation groove 775 of thevalve member 770. Accordingly, proximal movement of theelongated members 782 causes thevalve member 770 to move proximally, as shown by the arrow GG inFIG. 17 . The proximal movement of thevalve member 770 causes thehead 778 to be spaced apart from theseat surface 792, thereby allowing flow of the dermal filler through theopenings 776 and into thelumen 777 of thevalve member 770. Said another way, the proximal movement of thevalve member 770 causes thehead 778 to be spaced apart from theseat surface 792, thereby defining a medicament flow path (as shown by the dashed line inFIG. 17 ). - Moreover, when the
valve member 770 is moved proximally, theshoulder 779 exerts a force on the distal portion of thevalve seat 790, thereby causing the distal portion of thevalve seat 790 to deform. In this manner, the distalportion valve seat 790 acts as a biasing member to urge thevalve member 770 towards the first position. - The medicaments and/or dermal fillers described above can be any material suitable for augmenting soft tissue. In some embodiments, a medicament and/or dermal filler can include a pain reliever, such as, for example, lidocaine. In other embodiments, a medicament and/or dermal filler can include a colorant and/or a marker. For example, in some embodiments a medicament and/or dermal filler can include a radio-opaque marker. In other embodiments, a medicament and/or dermal filler can include a tattoo ink.
- In some embodiments, a dermal filler can include, for example, a side chain crystalline (SCC) polymer of the type disclosed in International Patent Application No. PCT/US2007/023226, entitled “Compositions, Devices and Methods for Modifying Soft Tissue,” which is incorporated herein by reference in its entirety. In other embodiments, a dermal filler can include hyaluronic acid. In yet other embodiments, a dermal filler can include polyacrylamide, collagen (either human and/or bovine), polymethylmethacrylate, silicone, calcium hydroxylapatite (CaHA), hydrophilic polyacrylamid gel (PAAG), and/or poly-L-lactic acid hydrogel (PLLA).
- In some embodiments, a dermal filler can include any of the following commercially-available dermal fillers: Puragen™ and its derivatives, produced by Mentor Corporation, Belotero® and its derivatives, produced by Merz Pharmaceuticals, BIO-ALCAMID™ and its derivatives, produced by Polymekon S.R.L., Outline® and its derivatives, produced by ProCytech, HylaNew® and its derivatives, produced by Prollenium Medical Technologies, Inc., Restylane® and its derivatives, produced by Q-Med or Medicis Pharmaceutical Corporation, Reviderm USA and its derivatives, produced by Rofil Medical International N.V., Teosyal® and its derivatives, produced by Teoxane Laboratories, Fascian® and its derivatives, produced by Fascia Biosystems, LLC, FG-5017 and its derivatives, produced by Fibrogen, Inc., Amazingel and its derivatives, produced by FuHua High Molecular Matter Company, Ltd., Laresse® Dermal Filler and its derivatives, produced by FzioMed, Inc., Zyderm® and its derivatives, produced by Inamed Corporation, Isolagen® and its derivatives, produced by Isolagen, Inc., MacDermol® and its derivatives, produced by Laboratories ORGéV, Juvéderm™ and its derivatives, produced by L.E.A. Derm, Hyaluderm® and its derivatives, produced by LCA Pharmaceutical, Silikon® 1000 and its derivatives, produced by Alcon, Inc., Esthèlis and its derivatives, produced by Antesis® S.A., Artefill® and its derivatives, produced by Artes Medical, Inc., Radiesse® and its derivatives, produced by BioForm Medical, Inc., Matridex® and its derivatives, produced by BioPolymer GmbH & Co. KG, Evolence® and its derivatives, produced by ColBar LifeScience Ltd., Aquamid® and its derivatives, produced by Contura International A/S, SurgiDerm® and its derivatives, produced by Labortoire Corneal® Development, Rhegecoll and its derivatives, produced by Dermabiol Institute of Kuhra Vital GmbH, DermaLive® and its derivatives, produced by Derma Tech, and/or Sculptra™ and its derivatives, produced by Dermik® Laboratories.
- While various embodiments have been described above, it should be understood that they have been presented by way of example only, and not limitation. Where methods described above indicate certain events occurring in certain order, the ordering of certain events may be modified. Additionally, certain of the events may be performed concurrently in a parallel process when possible, as well as performed sequentially as described above.
- Although the energy sources are shown and described above as including a pressurized fluid, in other embodiments, an energy source can include any suitable form of stored energy and/or a mechanism configured to convert energy from one form to another. For example, in some embodiments an energy source can include a source of stored electrical energy (e.g., a battery), a source of chemical energy (e.g., products that react to produce energy), and/or a source of mechanical energy (e.g., a spring). In other embodiments, an energy source can include a mechanism configured to convert electrical potential energy to a kinetic energy. For example, in some embodiments, an energy source can include an electric motor (e.g., a stepper motor) configured to receive electrical energy (from a battery or from an AC power source) and convert the electrical energy into a kinetic energy to move a piston.
- Although the medicament containers are shown and described above as including a piston, in other embodiments, a medicament container can be devoid of a piston. For example, in some embodiments, a fluid powered injection system can include a medicament container devoid of a piston, and include a source of pressurized fluid. The dermal filler contained within the medicament container can have a high viscosity such that it will not readily mix with the pressurized fluid. Accordingly, to actuate the injector, the pressurized fluid is conveyed into the medicament container and in direct contact with the dermal filler to be injected, thereby moving the dermal filler within the medicament container.
- Although the
coupling members 436 are shown and described as being configured to bend outwardly when thecoupler 433 is being coupled to themedicament container 410, in other embodiments, thecoupling members 436 can be substantially rigid. For example, in some embodiments, theflange 413 of themedicament container 410 does not extend circumferentially around themedicament container 410, but rather there may be two flanges positioned on opposite sides of themedicament container 410. In such embodiments, themedicament container 410 can be rotated relative to thehand piece 449 until the flanges are out of alignment with thecoupling members 436. Thehand piece 449 can then be disposed about themedicament container 410. Themedicament container 410 can then be rotated relative to thehand piece 449 until the flanges are aligned with thecoupling members 436, thereby securing the medicament container within thehand piece 449. - In some embodiments, for example, an apparatus includes a medicament container, a needle, an energy source, and a regulator. The medicament container has a piston movably disposed therein such that the medicament container is divided into a first portion and a second portion. The first portion of the medicament container is configured to contain a medicament, such as, for example a dermal filler. The needle is coupled to the medicament container such that the needle is in fluid communication with the first portion of the medicament container. The energy source is operatively coupled to the piston and is configured to produce a kinetic energy to move the piston within the medicament container such that the medicament having a viscosity of at least 1000 Poise (100 N-sec/m2) can be conveyed from the first portion of the medicament container through a distal end of the needle at a flow rate of at least 0.02 cubic centimeters per minute. The regulator is configured to regulate the flow rate of the medicament through the distal end of the needle.
- In some embodiments, for example, an apparatus includes a medical injector, a pressurized fluid source, and a regulator. The medical injector is configured to contain a dermal filler, and includes a needle. The needle defines a lumen therethrough having a nominal inner diameter of less than approximately 0.140 millimeters (i.e., the needle is smaller than 30 gauge), and has a length of at least 17 millimeters. The pressurized fluid source, which can include, for example, a canister of pressurized fluid, is operatively coupled to the medical injector. A pressurized fluid from the pressurized fluid source has a pressure of at least 345 kilopascals. The pressurized fluid is configured to actuate the medical injector such that the dermal filler can be conveyed from the medical injector through the lumen of the needle. The regulator is configured to regulate the flow rate of the dermal filler through the lumen of the needle.
- Although various embodiments have been described as having particular features and/or combinations of components, other embodiments are possible having a combination of any features and/or components from any of embodiments where appropriate. For example, in some embodiments, a medical device can include a remotely located source of pressurized fluid, such as the source of
pressurized fluid 351 shown and described above, and a regulator coupled to the medicament container, such as theregulator 760 shown and described above.
Claims (39)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/114,194 US20090124996A1 (en) | 2006-11-03 | 2008-05-02 | Apparatus and methods for injecting high viscosity dermal fillers |
PCT/US2008/072310 WO2009021020A1 (en) | 2007-08-08 | 2008-08-06 | Apparatus and methods for injecting high viscosity dermal fillers |
EP08797262A EP2183003A1 (en) | 2007-08-08 | 2008-08-06 | Apparatus and methods for injecting high viscosity dermal fillers |
AU2008283868A AU2008283868B2 (en) | 2007-08-08 | 2008-08-06 | Apparatus and methods for injecting high viscosity dermal fillers |
US12/477,527 US20090240200A1 (en) | 2006-11-03 | 2009-06-03 | Apparatus and methods for injecting high viscosity dermal fillers |
US12/871,405 US8343132B2 (en) | 2006-11-03 | 2010-08-30 | Apparatus and methods for injecting high viscosity dermal fillers |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85643006P | 2006-11-03 | 2006-11-03 | |
US85754606P | 2006-11-08 | 2006-11-08 | |
US85775506P | 2006-11-08 | 2006-11-08 | |
US96406607P | 2007-08-08 | 2007-08-08 | |
US99354107P | 2007-09-12 | 2007-09-12 | |
PCT/US2007/023226 WO2008066657A2 (en) | 2006-11-03 | 2007-11-01 | Compositions, devices and methods for modifying soft tissue |
US1622307P | 2007-12-21 | 2007-12-21 | |
US12/114,194 US20090124996A1 (en) | 2006-11-03 | 2008-05-02 | Apparatus and methods for injecting high viscosity dermal fillers |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/023226 Continuation-In-Part WO2008066657A2 (en) | 2006-11-03 | 2007-11-01 | Compositions, devices and methods for modifying soft tissue |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/477,527 Division US20090240200A1 (en) | 2006-11-03 | 2009-06-03 | Apparatus and methods for injecting high viscosity dermal fillers |
US12/871,405 Continuation US8343132B2 (en) | 2006-11-03 | 2010-08-30 | Apparatus and methods for injecting high viscosity dermal fillers |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090124996A1 true US20090124996A1 (en) | 2009-05-14 |
Family
ID=40341701
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/114,194 Abandoned US20090124996A1 (en) | 2006-11-03 | 2008-05-02 | Apparatus and methods for injecting high viscosity dermal fillers |
US12/477,527 Abandoned US20090240200A1 (en) | 2006-11-03 | 2009-06-03 | Apparatus and methods for injecting high viscosity dermal fillers |
US12/871,405 Expired - Fee Related US8343132B2 (en) | 2006-11-03 | 2010-08-30 | Apparatus and methods for injecting high viscosity dermal fillers |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/477,527 Abandoned US20090240200A1 (en) | 2006-11-03 | 2009-06-03 | Apparatus and methods for injecting high viscosity dermal fillers |
US12/871,405 Expired - Fee Related US8343132B2 (en) | 2006-11-03 | 2010-08-30 | Apparatus and methods for injecting high viscosity dermal fillers |
Country Status (4)
Country | Link |
---|---|
US (3) | US20090124996A1 (en) |
EP (1) | EP2183003A1 (en) |
AU (1) | AU2008283868B2 (en) |
WO (1) | WO2009021020A1 (en) |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080269105A1 (en) * | 2006-12-05 | 2008-10-30 | David Taft | Delivery of drugs |
US20090024550A1 (en) * | 2006-09-06 | 2009-01-22 | Devicescape Software, Inc. | Systems and Methods for Wireless Network Selection |
US20090198183A1 (en) * | 2006-11-03 | 2009-08-06 | Krumme John F | Apparatus and methods for injecting dermal fillers |
US20090204101A1 (en) * | 2007-08-20 | 2009-08-13 | Wortzman Mitchell S | Method of applying an injectable filler |
US20090252777A1 (en) * | 2006-12-05 | 2009-10-08 | Landec Corporation | Method for formulating a controlled-release pharmaceutical formulation |
US20090263346A1 (en) * | 2006-12-05 | 2009-10-22 | David Taft | Systems and methods for delivery of drugs |
US20090299328A1 (en) * | 2008-05-30 | 2009-12-03 | Allergan, Inc. | Injection device for soft-tissue augmentation fillers, bioactive agents and other biocompatible materials in liquid or gel form |
US20100004124A1 (en) * | 2006-12-05 | 2010-01-07 | David Taft | Systems and methods for delivery of materials for agriculture and aquaculture |
US20100016829A1 (en) * | 2008-07-15 | 2010-01-21 | Krumme John F | Apparatus and methods for retaining a needle on a medical injector |
US20110092916A1 (en) * | 2008-12-02 | 2011-04-21 | Allergan, Inc. | Injection device |
US20110178399A1 (en) * | 2008-08-13 | 2011-07-21 | Andrea Del Corso | Occlusion device for vascular surgery |
US8002753B2 (en) | 2007-12-21 | 2011-08-23 | Nordson Corporation | Self-contained pressurized injection device |
US8114883B2 (en) | 2007-12-04 | 2012-02-14 | Landec Corporation | Polymer formulations for delivery of bioactive materials |
US20120109072A1 (en) * | 2008-08-25 | 2012-05-03 | Denki Kagaku Kogyo Kabushiki Kaisha | Syringe |
US20120191036A1 (en) * | 2011-01-26 | 2012-07-26 | Chin Sae Hoon | Syringe for treating facial wrinkles and operation method using the same |
US8603028B2 (en) | 2011-11-18 | 2013-12-10 | Allergan, Inc. | Injection device having an angled tip portion |
US20140018770A1 (en) * | 2012-07-16 | 2014-01-16 | Howard Sutkin | Handheld medical substance dispensing system, apparatus and methods |
US8888751B2 (en) | 2009-12-07 | 2014-11-18 | Allergan, Inc. | Slotted syringe |
US8992481B2 (en) | 2010-05-19 | 2015-03-31 | Allergan, Inc. | Modular injection device |
US20150151045A1 (en) * | 2012-06-07 | 2015-06-04 | Consort Medical Plc | Method of manufacturing a propellant container |
US9095654B2 (en) | 2012-08-14 | 2015-08-04 | Allergan, Inc. | Syringe for mixing and dispensing adipose tissue |
US9114216B2 (en) | 2012-07-16 | 2015-08-25 | Accunit, Llc | Handheld medical substance dispensing system, apparatus and methods |
US20160081849A1 (en) * | 2014-09-18 | 2016-03-24 | Ethicon Endo-Surgery, Inc. | Therapeutic agent delivery device |
US20180289889A1 (en) * | 2012-04-10 | 2018-10-11 | Carebay Europe Ltd | Infusion device |
US10265477B2 (en) | 2013-05-23 | 2019-04-23 | Allergan, Inc. | Mechanical syringe accessory |
US10433928B2 (en) | 2015-03-10 | 2019-10-08 | Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company | Multiple needle injector |
USD865948S1 (en) | 2017-03-24 | 2019-11-05 | Allergan, Inc. | Syringe device |
US10596321B2 (en) | 2016-04-08 | 2020-03-24 | Allergan, Inc. | Aspiration and injection device |
US10792427B2 (en) | 2014-05-13 | 2020-10-06 | Allergan, Inc. | High force injection devices |
US11185641B2 (en) | 2014-10-01 | 2021-11-30 | Allergan, Inc. | Devices for injection and dosing |
US11684719B2 (en) | 2013-05-23 | 2023-06-27 | Allergan, Inc. | Methods of treatment using a syringe extrusion accessory |
US11684725B2 (en) | 2018-12-19 | 2023-06-27 | Fenwal, Inc. | Disposable syringe for use with pneumatic drivers |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7947017B2 (en) | 2004-11-22 | 2011-05-24 | Intelliject, Inc. | Devices, systems and methods for medicament delivery |
US10737028B2 (en) | 2004-11-22 | 2020-08-11 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US7648483B2 (en) | 2004-11-22 | 2010-01-19 | Intelliject, Inc. | Devices, systems and methods for medicament delivery |
US11590286B2 (en) | 2004-11-22 | 2023-02-28 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
GB2434548B (en) | 2004-11-22 | 2009-04-08 | Intelliject Inc | Devices, systems, and methods for medicament delivery |
US9022980B2 (en) | 2005-02-01 | 2015-05-05 | Kaleo, Inc. | Medical injector simulation device |
US8231573B2 (en) | 2005-02-01 | 2012-07-31 | Intelliject, Inc. | Medicament delivery device having an electronic circuit system |
US8206360B2 (en) | 2005-02-01 | 2012-06-26 | Intelliject, Inc. | Devices, systems and methods for medicament delivery |
US8361026B2 (en) | 2005-02-01 | 2013-01-29 | Intelliject, Inc. | Apparatus and methods for self-administration of vaccines and other medicaments |
DK2058020T3 (en) | 2005-02-01 | 2013-01-07 | Intelliject Inc | Device for administering drug |
US8157807B2 (en) * | 2005-06-02 | 2012-04-17 | The Invention Science Fund I, Llc | Skin treatment including patterned light |
US8679101B2 (en) | 2005-03-04 | 2014-03-25 | The Invention Science Fund I, Llc | Method and system for temporary hair removal |
US20060276859A1 (en) * | 2005-06-02 | 2006-12-07 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Photopatterning of skin |
US8529560B2 (en) * | 2005-03-04 | 2013-09-10 | The Invention Science Fund I, Llc | Hair treatment system |
US20060200114A1 (en) * | 2005-03-04 | 2006-09-07 | Searete Llc, A Limited Liability Corporation Of State Of Delaware | Hair removal system with light source array |
US8540701B2 (en) * | 2005-03-04 | 2013-09-24 | The Invention Science Fund I, Llc | Hair treatment system |
US9055958B2 (en) * | 2005-06-29 | 2015-06-16 | The Invention Science Fund I, Llc | Hair modification using converging light |
US20090124996A1 (en) * | 2006-11-03 | 2009-05-14 | Scott Heneveld | Apparatus and methods for injecting high viscosity dermal fillers |
US20090246155A1 (en) * | 2006-12-05 | 2009-10-01 | Landec Corporation | Compositions and methods for personal care |
WO2008091838A2 (en) | 2007-01-22 | 2008-07-31 | Intelliject, Inc. | Medical injector with compliance tracking and monitoring |
USD994111S1 (en) | 2008-05-12 | 2023-08-01 | Kaleo, Inc. | Medicament delivery device cover |
US8939943B2 (en) | 2011-01-26 | 2015-01-27 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
US9084849B2 (en) | 2011-01-26 | 2015-07-21 | Kaleo, Inc. | Medicament delivery devices for administration of a medicament within a prefilled syringe |
US8627816B2 (en) | 2011-02-28 | 2014-01-14 | Intelliject, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
US20120279996A1 (en) * | 2011-05-06 | 2012-11-08 | Nordson Corporation | Adapter for syringes and associated dispensing devices and methods |
US9522235B2 (en) | 2012-05-22 | 2016-12-20 | Kaleo, Inc. | Devices and methods for delivering medicaments from a multi-chamber container |
WO2014100837A1 (en) | 2012-12-17 | 2014-06-26 | Bui The Duy | Computer aided implantation of body implants |
GB2519973B (en) * | 2013-11-01 | 2017-06-14 | Consort Medical Plc | Medicament delivery device sub-assembly |
US9561095B1 (en) * | 2015-10-12 | 2017-02-07 | Phi Nguyen | Body augmentation device |
WO2015171964A1 (en) * | 2014-05-07 | 2015-11-12 | Sri International | Needle free injection device |
US9517307B2 (en) | 2014-07-18 | 2016-12-13 | Kaleo, Inc. | Devices and methods for delivering opioid antagonists including formulations for naloxone |
EP3274021B1 (en) | 2015-03-24 | 2024-02-14 | Kaleo, Inc. | Devices and methods for delivering a lyophilized medicament |
EP3316928B1 (en) | 2015-06-30 | 2022-10-19 | Kaleo, Inc. | Auto-injectors for administration of a medicament within a prefilled syringe |
US20170103184A1 (en) * | 2015-10-12 | 2017-04-13 | Phi Nguyen | Injectable filler |
US10688244B2 (en) | 2016-12-23 | 2020-06-23 | Kaleo, Inc. | Medicament delivery device and methods for delivering drugs to infants and children |
AU2020331302A1 (en) | 2019-08-09 | 2022-01-06 | Kaleo, Inc. | Devices and methods for delivery of substances within a prefilled syringe |
WO2021173838A1 (en) * | 2020-02-28 | 2021-09-02 | Advanced Aesthetic Technologies, Inc. | Methods, kits and compositions for novel agarose-based dermal filler with enhanced rheological properties providing safety features |
Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2390246A (en) * | 1940-10-18 | 1945-12-04 | Marvin L Folkman | Syringe |
US2605763A (en) * | 1948-01-31 | 1952-08-05 | Becton Dickinson Co | Injection device |
US4332246A (en) * | 1980-06-30 | 1982-06-01 | Staodynamics, Inc. | Positive displacement intravenous infusion pump device and method |
US4351335A (en) * | 1979-04-16 | 1982-09-28 | Whitney Douglass G | Injection device and method |
US4861340A (en) * | 1988-10-17 | 1989-08-29 | Cordis Corporation | Hand-held pneumatic power assisted syringe |
US5019037A (en) * | 1989-07-06 | 1991-05-28 | Alcon Laboratories, Inc. | Pneumatic retinopexy injector |
US5383930A (en) * | 1991-03-29 | 1995-01-24 | Collagen Corporation | Method for treating fine superficial facial lines |
US5833661A (en) * | 1992-03-31 | 1998-11-10 | Matef | Medical or veterinary injection device |
US6616627B2 (en) * | 2000-01-07 | 2003-09-09 | Biovalve Technologies, Inc. | Injection device |
US6644625B1 (en) * | 2000-08-11 | 2003-11-11 | L. R. Nelson | Pistol grip hose nozzle with proportional flow control |
US20030233070A1 (en) * | 2001-11-09 | 2003-12-18 | De La Serna Pedro E. | Pneumatic powered autoinjector |
US6736792B1 (en) * | 1997-01-27 | 2004-05-18 | James Zhou Liu | Nasal-nasopharyngeal-cleaning system |
US20040225276A1 (en) * | 2003-03-13 | 2004-11-11 | Burgess Cheryl M. | Methods of administering a material into a patient for dermal enhancement |
US20050070848A1 (en) * | 2003-05-28 | 2005-03-31 | Ducksoo Kim | Self-contained power-assisted syringe |
US20050085767A1 (en) * | 2002-02-12 | 2005-04-21 | Karim Menassa | Needleless injector |
US6938795B2 (en) * | 2003-11-26 | 2005-09-06 | Nordson Corporation | Hand-held fluid dispenser system and method of operating hand-held fluid dispenser systems |
US20050267403A1 (en) * | 2004-05-28 | 2005-12-01 | Sergio Landau | Needle-free injection system |
US7195610B1 (en) * | 2001-09-17 | 2007-03-27 | Cardinal Health 303, Inc. | Pneumatic syringe driver |
US20070149925A1 (en) * | 2004-11-22 | 2007-06-28 | Edwards Evan T | Devices, systems, and methods for medicament delivery |
US20090177158A1 (en) * | 2007-12-21 | 2009-07-09 | Krumme John F | Self-contained pressurized injection device |
US20090240200A1 (en) * | 2006-11-03 | 2009-09-24 | Scott Heneveld | Apparatus and methods for injecting high viscosity dermal fillers |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2469642A (en) | 1944-09-23 | 1949-05-10 | Edward A Grewe | Blowgun |
US2670241A (en) | 1951-05-22 | 1954-02-23 | George S Pyles | Flow gun |
US3258176A (en) | 1964-09-24 | 1966-06-28 | Zenith Radio Corp | Pneumatic glue dispenser |
US3827604A (en) | 1972-09-11 | 1974-08-06 | Nordson Corp | Modular solenoid-operated dispenser |
US4260130A (en) | 1979-07-30 | 1981-04-07 | B & G Equipment Company | Valve for corrosive fluids |
US4735619A (en) | 1982-09-13 | 1988-04-05 | Sperry C R | Syringe and syringe actuator |
DE3416105A1 (en) | 1984-04-30 | 1985-11-07 | Meltex Verbindungstechnik GmbH, 2120 Lüneburg | MELT ADHESIVE HOSE |
US4634027A (en) | 1985-01-04 | 1987-01-06 | Mvm Valve Co., Inc. | Liquid dispensing apparatus and an anti-drip valve cartridge therefor |
US4636198A (en) | 1985-11-18 | 1987-01-13 | Mallinckrodt, Inc. | Power syringe with volume reducing adapter |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US5066276A (en) | 1988-06-21 | 1991-11-19 | Alcon Laboratories, Inc. | Method and apparatus for injecting viscous fluid into the eye to lift pre-retinal and post-retinal membrane with linear pressure control |
US4932592A (en) | 1988-10-04 | 1990-06-12 | Stripping Technologies Inc. | Pressurized hose handle with reverse grip |
US4944726A (en) | 1988-11-03 | 1990-07-31 | Applied Vascular Devices | Device for power injection of fluids |
JP3204455B2 (en) | 1989-05-11 | 2001-09-04 | ランデック コーポレイション | Temperature activated adhesive assembly |
US4993948A (en) | 1989-10-30 | 1991-02-19 | Cameron Frederick J | Applicator for dental material |
US5074443A (en) | 1989-12-20 | 1991-12-24 | Nordson Corporation | Adaptor for liquid dispensing syringe |
US5204382A (en) | 1992-02-28 | 1993-04-20 | Collagen Corporation | Injectable ceramic compositions and methods for their preparation and use |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5469867A (en) | 1992-09-02 | 1995-11-28 | Landec Corporation | Cast-in place thermoplastic channel occluder |
US5383605A (en) | 1992-12-10 | 1995-01-24 | Hydro-Chem Systems, Inc. | Radio controlled spraying device |
US5375738A (en) | 1993-10-27 | 1994-12-27 | Nordson Corporation | Apparatus for dispensing heated fluid materials |
US5535919A (en) | 1993-10-27 | 1996-07-16 | Nordson Corporation | Apparatus for dispensing heated fluid materials |
US5370630A (en) | 1993-11-12 | 1994-12-06 | Smidebush; Michael J. | Device for injection of fluidic materials into body tissue |
US5540657A (en) | 1994-07-15 | 1996-07-30 | Collagen Corporation | Delivery device for injectable materials |
US5637095A (en) | 1995-01-13 | 1997-06-10 | Minimed Inc. | Medication infusion pump with flexible drive plunger |
DE29606540U1 (en) | 1996-04-10 | 1997-08-07 | Mühlbauer, Ernst, 22547 Hamburg | Dental mass application device |
US5830194A (en) | 1996-09-20 | 1998-11-03 | Azam Anwar | Power syringe |
US6146361A (en) | 1996-09-26 | 2000-11-14 | Becton Dickinson And Company | Medication delivery pen having a 31 gauge needle |
ZA9811087B (en) | 1997-12-04 | 1999-06-03 | Bracco Research Sa | Automatic liquid injection system and method |
US6152386A (en) | 1998-11-06 | 2000-11-28 | Nordson Corporation | Handgun and hose assembly for dispensing liquids |
US7018365B2 (en) | 1999-05-21 | 2006-03-28 | Micro Therapeutics, Inc. | Threaded syringe with quick stop |
US6355024B1 (en) | 1999-07-14 | 2002-03-12 | Mallinckrodt Inc. | Medical fluid delivery system |
US7101928B1 (en) | 1999-09-17 | 2006-09-05 | Landec Corporation | Polymeric thickeners for oil-containing compositions |
US6210359B1 (en) | 2000-01-21 | 2001-04-03 | Jet Medica, L.L.C. | Needleless syringe |
US6379152B1 (en) | 2000-04-19 | 2002-04-30 | Centrix, Inc. | Dental capsule for placement of ultra-high viscosity dental composite material |
CA2409711A1 (en) | 2000-05-18 | 2001-11-22 | Dentsply International, Inc. | Fluid material dispensing syringe |
US6550480B2 (en) | 2001-01-31 | 2003-04-22 | Numed/Tech Llc | Lumen occluders made from thermodynamic materials |
US7041084B2 (en) | 2001-05-24 | 2006-05-09 | Fojtik Shawn P | Hand-held, hand operated power syringe and methods |
CA2455525C (en) | 2001-07-24 | 2007-12-04 | Artes Medical Usa, Inc. | Elongated syringe |
JP2003054279A (en) | 2001-08-10 | 2003-02-26 | Honda Motor Co Ltd | Control device of front and rear wheel drive vehicle |
US6662969B2 (en) | 2001-12-14 | 2003-12-16 | Zaxis, Inc. | Hydraulically and volumetrically dispensing a target fluid |
DE10202367A1 (en) | 2002-01-23 | 2003-09-25 | Duerr Dental Gmbh Co Kg | Applicator for liquid or viscous substances |
US6780170B2 (en) | 2002-05-15 | 2004-08-24 | Liebel-Flarsheim Company | Hydraulic remote for a medical fluid injector |
EP1545661A2 (en) * | 2002-09-12 | 2005-06-29 | Children's Hospital Medical Center | Method and device for painless injection of medication |
US7270648B2 (en) * | 2002-12-23 | 2007-09-18 | Farhad Kazemzadeh | Drug delivery apparatus |
US6997904B2 (en) | 2002-12-24 | 2006-02-14 | Robert David Sculati | Viscous fluid injection system |
US6772575B2 (en) * | 2002-12-30 | 2004-08-10 | Lantech Management Corp. And Lantech Holding Corp. | Shrink wrap apparatus and method of shrink wrapping products |
AU2003205326A1 (en) | 2003-01-24 | 2004-08-23 | Alza Corporation | Pneumatic powered autoinjector |
WO2004080357A1 (en) * | 2003-03-14 | 2004-09-23 | Ferreyro Irigoyen Roque Humber | Hydraulic device for the injection of bone cement in percutaneous vertebroplasty |
US8021334B2 (en) * | 2004-05-30 | 2011-09-20 | Nilimedix Ltd. | Drug delivery device and method |
US7678089B2 (en) * | 2003-11-14 | 2010-03-16 | Medical Instill Technologies, Inc. | Delivery device and method of delivery |
CN101912325A (en) | 2004-01-12 | 2010-12-15 | i科学外科公司 | Injector for viscous materials |
US8998881B2 (en) | 2005-08-10 | 2015-04-07 | Alza Corporation | Method for delivering drugs to tissue under microjet propulsion |
CA2658544C (en) | 2005-09-07 | 2012-12-11 | The Royal Institution For The Advancement Of Learning/Mcgill University | Device for injecting high viscosity material |
US7748567B2 (en) | 2006-03-29 | 2010-07-06 | Nordson Corporation | Single dose dual fluid cartridge for use with hand-held applicators |
WO2008066657A2 (en) | 2006-11-03 | 2008-06-05 | Aesthetic Sciences Corporation | Compositions, devices and methods for modifying soft tissue |
US7658722B2 (en) | 2007-08-10 | 2010-02-09 | Coeur, Inc. | Adapter for power injectors |
-
2008
- 2008-05-02 US US12/114,194 patent/US20090124996A1/en not_active Abandoned
- 2008-08-06 EP EP08797262A patent/EP2183003A1/en not_active Withdrawn
- 2008-08-06 AU AU2008283868A patent/AU2008283868B2/en not_active Ceased
- 2008-08-06 WO PCT/US2008/072310 patent/WO2009021020A1/en active Application Filing
-
2009
- 2009-06-03 US US12/477,527 patent/US20090240200A1/en not_active Abandoned
-
2010
- 2010-08-30 US US12/871,405 patent/US8343132B2/en not_active Expired - Fee Related
Patent Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2390246A (en) * | 1940-10-18 | 1945-12-04 | Marvin L Folkman | Syringe |
US2605763A (en) * | 1948-01-31 | 1952-08-05 | Becton Dickinson Co | Injection device |
US4351335A (en) * | 1979-04-16 | 1982-09-28 | Whitney Douglass G | Injection device and method |
US4332246A (en) * | 1980-06-30 | 1982-06-01 | Staodynamics, Inc. | Positive displacement intravenous infusion pump device and method |
US4861340A (en) * | 1988-10-17 | 1989-08-29 | Cordis Corporation | Hand-held pneumatic power assisted syringe |
US5019037A (en) * | 1989-07-06 | 1991-05-28 | Alcon Laboratories, Inc. | Pneumatic retinopexy injector |
US5383930A (en) * | 1991-03-29 | 1995-01-24 | Collagen Corporation | Method for treating fine superficial facial lines |
US5833661A (en) * | 1992-03-31 | 1998-11-10 | Matef | Medical or veterinary injection device |
US6736792B1 (en) * | 1997-01-27 | 2004-05-18 | James Zhou Liu | Nasal-nasopharyngeal-cleaning system |
US6616627B2 (en) * | 2000-01-07 | 2003-09-09 | Biovalve Technologies, Inc. | Injection device |
US6644625B1 (en) * | 2000-08-11 | 2003-11-11 | L. R. Nelson | Pistol grip hose nozzle with proportional flow control |
US7195610B1 (en) * | 2001-09-17 | 2007-03-27 | Cardinal Health 303, Inc. | Pneumatic syringe driver |
US20030233070A1 (en) * | 2001-11-09 | 2003-12-18 | De La Serna Pedro E. | Pneumatic powered autoinjector |
US20050085767A1 (en) * | 2002-02-12 | 2005-04-21 | Karim Menassa | Needleless injector |
US20040225276A1 (en) * | 2003-03-13 | 2004-11-11 | Burgess Cheryl M. | Methods of administering a material into a patient for dermal enhancement |
US20050070848A1 (en) * | 2003-05-28 | 2005-03-31 | Ducksoo Kim | Self-contained power-assisted syringe |
US6938795B2 (en) * | 2003-11-26 | 2005-09-06 | Nordson Corporation | Hand-held fluid dispenser system and method of operating hand-held fluid dispenser systems |
US20050267403A1 (en) * | 2004-05-28 | 2005-12-01 | Sergio Landau | Needle-free injection system |
US20070149925A1 (en) * | 2004-11-22 | 2007-06-28 | Edwards Evan T | Devices, systems, and methods for medicament delivery |
US20090240200A1 (en) * | 2006-11-03 | 2009-09-24 | Scott Heneveld | Apparatus and methods for injecting high viscosity dermal fillers |
US20090177158A1 (en) * | 2007-12-21 | 2009-07-09 | Krumme John F | Self-contained pressurized injection device |
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090024550A1 (en) * | 2006-09-06 | 2009-01-22 | Devicescape Software, Inc. | Systems and Methods for Wireless Network Selection |
US20090198183A1 (en) * | 2006-11-03 | 2009-08-06 | Krumme John F | Apparatus and methods for injecting dermal fillers |
US8956602B2 (en) | 2006-12-05 | 2015-02-17 | Landec, Inc. | Delivery of drugs |
US20090252777A1 (en) * | 2006-12-05 | 2009-10-08 | Landec Corporation | Method for formulating a controlled-release pharmaceutical formulation |
US20090263346A1 (en) * | 2006-12-05 | 2009-10-22 | David Taft | Systems and methods for delivery of drugs |
US8524259B2 (en) | 2006-12-05 | 2013-09-03 | Landec Corporation | Systems and methods for delivery of materials |
US20100004124A1 (en) * | 2006-12-05 | 2010-01-07 | David Taft | Systems and methods for delivery of materials for agriculture and aquaculture |
US20080269105A1 (en) * | 2006-12-05 | 2008-10-30 | David Taft | Delivery of drugs |
US8399007B2 (en) | 2006-12-05 | 2013-03-19 | Landec Corporation | Method for formulating a controlled-release pharmaceutical formulation |
US20090204101A1 (en) * | 2007-08-20 | 2009-08-13 | Wortzman Mitchell S | Method of applying an injectable filler |
US8114883B2 (en) | 2007-12-04 | 2012-02-14 | Landec Corporation | Polymer formulations for delivery of bioactive materials |
US8002753B2 (en) | 2007-12-21 | 2011-08-23 | Nordson Corporation | Self-contained pressurized injection device |
US20110137286A1 (en) * | 2008-05-30 | 2011-06-09 | Allergan, Inc. | Injection device for soft-tissue augmentation fillers, bioactive agents and other biocompatible materials in liquid or gel form |
US10279162B2 (en) | 2008-05-30 | 2019-05-07 | Allergan, Inc. | Injection device for soft-tissue augmentation fillers, bioactive agents and other biocompatible materials in liquid or gel form |
US8801659B2 (en) | 2008-05-30 | 2014-08-12 | Allergan, Inc. | Injection device for soft-tissue augmentation fillers, bioactive agents and other biocompatible materials in liquid or gel form |
US20090299328A1 (en) * | 2008-05-30 | 2009-12-03 | Allergan, Inc. | Injection device for soft-tissue augmentation fillers, bioactive agents and other biocompatible materials in liquid or gel form |
US20100016829A1 (en) * | 2008-07-15 | 2010-01-21 | Krumme John F | Apparatus and methods for retaining a needle on a medical injector |
US20110178399A1 (en) * | 2008-08-13 | 2011-07-21 | Andrea Del Corso | Occlusion device for vascular surgery |
US9332975B2 (en) * | 2008-08-13 | 2016-05-10 | Andrea Del Corso | Occlusion device for vascular surgery |
US20120109072A1 (en) * | 2008-08-25 | 2012-05-03 | Denki Kagaku Kogyo Kabushiki Kaisha | Syringe |
US11992668B2 (en) | 2008-12-02 | 2024-05-28 | Allergan, Inc. | Injection device |
US10232129B2 (en) | 2008-12-02 | 2019-03-19 | Allergan, Inc. | Injection device |
US20110092916A1 (en) * | 2008-12-02 | 2011-04-21 | Allergan, Inc. | Injection device |
US8888751B2 (en) | 2009-12-07 | 2014-11-18 | Allergan, Inc. | Slotted syringe |
US8992481B2 (en) | 2010-05-19 | 2015-03-31 | Allergan, Inc. | Modular injection device |
US20140309582A1 (en) * | 2011-01-26 | 2014-10-16 | Sae Hoon CHIN | Syringe for Treating Facial Wrinkles and Operation Method Using the Same |
US9610408B2 (en) * | 2011-01-26 | 2017-04-04 | Sae Hoon CHIN | Syringe for treating facial wrinkles and operation method using the same |
US9162028B2 (en) * | 2011-01-26 | 2015-10-20 | Sae Hoon CHIN | Syringe for treating facial wrinkles and operation method using the same |
US20120191036A1 (en) * | 2011-01-26 | 2012-07-26 | Chin Sae Hoon | Syringe for treating facial wrinkles and operation method using the same |
US9468720B2 (en) | 2011-11-18 | 2016-10-18 | Allergan, Inc. | Injection device having an angled tip portion |
US8603028B2 (en) | 2011-11-18 | 2013-12-10 | Allergan, Inc. | Injection device having an angled tip portion |
US10518029B2 (en) * | 2012-04-10 | 2019-12-31 | Shl Medical Ag | Infusion device |
US11439748B2 (en) | 2012-04-10 | 2022-09-13 | Shl Medical Ag | Infusion device |
US20180289889A1 (en) * | 2012-04-10 | 2018-10-11 | Carebay Europe Ltd | Infusion device |
US20150151045A1 (en) * | 2012-06-07 | 2015-06-04 | Consort Medical Plc | Method of manufacturing a propellant container |
US9114216B2 (en) | 2012-07-16 | 2015-08-25 | Accunit, Llc | Handheld medical substance dispensing system, apparatus and methods |
US9821122B2 (en) | 2012-07-16 | 2017-11-21 | Accunit, Llc | Handheld medical substance dispensing system, apparatus and methods |
US20140018770A1 (en) * | 2012-07-16 | 2014-01-16 | Howard Sutkin | Handheld medical substance dispensing system, apparatus and methods |
US9724479B2 (en) * | 2012-07-16 | 2017-08-08 | Accunit, Llc | Handheld medical substance dispensing system, apparatus and methods |
US9095654B2 (en) | 2012-08-14 | 2015-08-04 | Allergan, Inc. | Syringe for mixing and dispensing adipose tissue |
US10265477B2 (en) | 2013-05-23 | 2019-04-23 | Allergan, Inc. | Mechanical syringe accessory |
US11684719B2 (en) | 2013-05-23 | 2023-06-27 | Allergan, Inc. | Methods of treatment using a syringe extrusion accessory |
US10792427B2 (en) | 2014-05-13 | 2020-10-06 | Allergan, Inc. | High force injection devices |
US20160081849A1 (en) * | 2014-09-18 | 2016-03-24 | Ethicon Endo-Surgery, Inc. | Therapeutic agent delivery device |
US10258502B2 (en) * | 2014-09-18 | 2019-04-16 | Orbit Biomedical Limited | Therapeutic agent delivery device |
US11337852B2 (en) | 2014-09-18 | 2022-05-24 | Gyroscope Therapeutics Limited | Therapeutic agent delivery device |
US11185641B2 (en) | 2014-10-01 | 2021-11-30 | Allergan, Inc. | Devices for injection and dosing |
US10433928B2 (en) | 2015-03-10 | 2019-10-08 | Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company | Multiple needle injector |
US10596321B2 (en) | 2016-04-08 | 2020-03-24 | Allergan, Inc. | Aspiration and injection device |
US11890457B2 (en) | 2016-04-08 | 2024-02-06 | Allergan, Inc. | Aspiration and injection device |
USD865950S1 (en) | 2017-03-24 | 2019-11-05 | Allergan, Inc. | Syringe device |
USD866753S1 (en) | 2017-03-24 | 2019-11-12 | Allergan, Inc. | Syringe device |
USD865948S1 (en) | 2017-03-24 | 2019-11-05 | Allergan, Inc. | Syringe device |
USD865949S1 (en) | 2017-03-24 | 2019-11-05 | Allergan, Inc. | Syringe device |
USD867582S1 (en) | 2017-03-24 | 2019-11-19 | Allergan, Inc. | Syringe device |
US11684725B2 (en) | 2018-12-19 | 2023-06-27 | Fenwal, Inc. | Disposable syringe for use with pneumatic drivers |
US11904147B2 (en) | 2018-12-19 | 2024-02-20 | Fenwal, Inc. | Methods and systems for mating disposable syringes with pneumatic drivers without breaking sterility |
Also Published As
Publication number | Publication date |
---|---|
EP2183003A1 (en) | 2010-05-12 |
AU2008283868B2 (en) | 2013-11-28 |
US20090240200A1 (en) | 2009-09-24 |
US8343132B2 (en) | 2013-01-01 |
WO2009021020A1 (en) | 2009-02-12 |
US20100324531A1 (en) | 2010-12-23 |
AU2008283868A1 (en) | 2009-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8343132B2 (en) | Apparatus and methods for injecting high viscosity dermal fillers | |
US8002753B2 (en) | Self-contained pressurized injection device | |
US8998849B2 (en) | Medical injector and adapter for coupling a medicament container and an actuator | |
US20090198183A1 (en) | Apparatus and methods for injecting dermal fillers | |
JP4780034B2 (en) | Needleless syringe | |
TWI224517B (en) | Pneumatic powered autoinjector | |
US8951229B2 (en) | Pressure actuated catheter seal and method for the same | |
US11992652B2 (en) | Self-powered syringe drivers | |
JP2023526316A (en) | Delivery of Fluids to the Ocular Channels | |
JP2019514654A5 (en) | ||
US20120259313A1 (en) | Apparatus and methods for limiting pressure and flow within a medical injector | |
US20100016829A1 (en) | Apparatus and methods for retaining a needle on a medical injector | |
US11167089B2 (en) | Reduced sputtering syringe | |
US20240238011A1 (en) | Anesthetic Tunneling Tool | |
WO2021252841A1 (en) | Device for controlled injection across a variety of material properties | |
JP2012062762A (en) | Disposable liquid supply pump |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THERAPEUTICS, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SMITH, STACY R.;REEL/FRAME:021396/0567 Effective date: 20080715 Owner name: AESTHETIC SCIENCES CORPORATION, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THERAPEUTICS, INC.;REEL/FRAME:021396/0572 Effective date: 20080715 Owner name: AESTHETIC SCIENCES CORPORATION, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HENEVELD, SCOTT;KRUMME, JOHN F.;WALTON, CHRISTIAN;REEL/FRAME:021396/0580;SIGNING DATES FROM 20080711 TO 20080813 |
|
AS | Assignment |
Owner name: SILICON VALLEY BANK, CALIFORNIA Free format text: SECURITY AGREEMENT;ASSIGNOR:AESTHETIC SCIENCES CORPORATION;REEL/FRAME:022504/0987 Effective date: 20090327 Owner name: SILICON VALLEY BANK,CALIFORNIA Free format text: SECURITY AGREEMENT;ASSIGNOR:AESTHETIC SCIENCES CORPORATION;REEL/FRAME:022504/0987 Effective date: 20090327 |
|
AS | Assignment |
Owner name: NORDSON EFD LLC, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AESTHETIC SCIENCES CORPORATION;REEL/FRAME:024950/0864 Effective date: 20100716 |
|
AS | Assignment |
Owner name: NORDSON CORPORATION, OHIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NORDSON EFD LLC;REEL/FRAME:024959/0157 Effective date: 20100909 |
|
STCB | Information on status: application discontinuation |
Free format text: EXPRESSLY ABANDONED -- DURING PUBLICATION PROCESS |
|
AS | Assignment |
Owner name: AESTHETIC SCIENCES CORPORATION, CALIFORNIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:SILICON VALLEY BANK;REEL/FRAME:025604/0642 Effective date: 20101122 |